CLONING AND SEQUENCING OF ALLERGENS OF DERMATOPHAGOIDES (HOUSE DUST MITE)

Abstract: The present invention features isolated DNA encoding allergens of (Dermatophagoides) (house dust mites) particularly of the species (Dermatophagoides farinae) and (Dermatophagoides pteronyssinus), which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, the invention provides DNA encoding the major (D. farinae) allergens, (Der f) I and (Der f) II and DNA encoding the major (D. pteronyssinus) allergens, (Der p) I and (Der p) II. The present invention further relates to proteins and peptides encoded by the isolated (D. farinae) and (D. pteronyssinus) DNA, including proteins containing sequence polymorphisms. In addition, the proteins or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens, are disclosed.

Description: CLONTNG AND SEQUENCING OF ALLERGENS OF DERMATOPHAGOIDES (ΗOUSE DUST MITE) Description Background Recent reports have documented the importance of responses to the Group I and Group II allergens in house dust mite allergy. For example, it has been documented that over 60% of patients have at least 50% of their anti-mite antibodies directed towards these proteins (Lind, P. et al.. Allergy. 12:259-274 (1984); van der Zee, J.S. et al.. J. Allergy Clin. Immunol.. £1:884-896 (1988)). It is possible that children show a greater degree of reactivity (Thompson, P.J. et al.. Immunology 6.4:311-314 (1988)). Allergy to mites of the genus Dermatophagoides .) is associated with conditions such as asthma, rhinitis and ectopic dermatitis. Two species, D. pteronyssinus and P. farinae. predominate and, as a result, considerable effort has been expended in trying to identify the allergens produced by these two species. D. pteronyssinus mites are the most common Dermatophagoides species in house dust in Western Europe and Australia. The species D. farinae predominates in other countries, such as North America and Japan (Wharton, G.W., J. Medical Entom. 12:577-621 (1976)). It has long been recognized that allergy to mites of this genus is associated with diseases such as asthma, rhinitis and atopic dermatitis. It is still not clear what allergens produced by these mites are responsible for the allergic response and associated conditions. Summary of the Invention The present invention relates to isolated DNA which encodes a protein allergen of Dermatophagoides ((D.) house dust mite) or a peptide which includes at least one epitope of a protein allergen of a house dust mite of the genus Dermatophagoides. It particularly relates to DNA encoding major allergens of the species D. farinae. designated Der fl and Der f II. or portions of these major allergens (i.e., peptides which include at least one epitope of Der f I or of Deι_f II). It also particularly relates to DNA encoding major allergens of D. pteronyssinus. designated Der p I and Der p II, or portions of these major allergens (i.e., peptides which include at least one epitope of Ω≤ P I or of Der p II). The present invention further relates to proteins and peptides encoded by the isolated Dermatophagoides (e.g., D. farinae. D. pteronyssinus) DNA including proteins containing sequence polymorphisms. Several nucleotide and resulting amino acid sequence polymorphisms have been discovered in the Der I, Der p II and Der f II allergens. All such nucleotide variations and proteins, or portions thereof, containing a sequence polymorphism are within the scope of the invention. Peptides of the present invention include at least one epitope of a D. farinae allergen (e.g., at least one epitope of Der f I or Deri " II) or at least one epitope of a P. pteronyssinus allergen (e.g., at least one epitope of Der p I or of Der p II). It also relates to antibodies specific for P. farinae proteins or peptides and to antibodies specific for P. pteronyssinus proteins or peptides. Permatophagoides PNA, proteins and peptides of the present invention are useful for diagnostic and therapeutic purposes. For example, isolated P. farinae proteins or peptides can be used to detect sensitivity in an individual to house dust mites and can be used to treat sensitivity (reduce sensitivity or desensitize) in an individual, to whom therapeutically effective quantities of the P. farinae protein or peptide is administered. For example, isolated P. farinae protein allergen, such as Per f I or Per f II. can be administered periodically, using standard techniques, to an individual in order to desensitize the individual. Alternatively, a peptide which includes at least one epitope of Per f I or of P_sι-f II can be administered for this purpose. Isolated P. pteronyssinus protein allergen, such as Per p I or Per p II, can be administered as described for Per f I or Per f II. Similarly, a peptide which includes at least one Per p I epitope or at least one Per p II epitope can be administered for this purpose. A combination of these proteins or peptides (e.g., Der-f I and Per f II: Per p I and Per p II; or a mixture of both Per f and Per p proteins) can also be administered. The use of such isolated proteins or peptides provides a means of desensitizing individuals to important house dust mite allergens. Brief Pescription of the Prawings Figures 1A and IB show the nucleotide and predicted amino acid sequence of cPNA ggtl 1 pl(13T) (SEQ IP NOS: 1 and 2, respectively). Numbers to the right are nucleotide positions whereas numbers above the sequence are amino acid positions. Positive amino acid residue numbers correspond to the sequence of the mature excreted Per p I beginning with threonine. Negative sequence numbers refer to the proposed transient pre- and preproenzyme forms of Per p I. The arrows indicate the beginning of the proposed proenzyme sequence and the mature Per p I, respectively. Residues -15 to -13 enclosed by an open box make up the proposed cleavage for the proenzyme formation, and the dashed residues 52-54 represent a potential N-glycosylation site. The termination TAA codon and the adjacent polyadenylation signal are underlined. Amino acid residues 1-41, 79-95, 11 1-142, and 162-179 correspond to known tryptic peptide sequences determined by conventional amino acid sequencing analysis. Figure 2 shows the restriction map of the cPNA insert of clone ggtl 1 pl(13T) and the strategy of PNA sequencing. Arrows indicate directions in which sequences were read. Figure 3 is a comparison of N-terminal sequences of Per p I and Per f I. The amino acid sequence for Per p I is equivalent to amino acids 1-20 in Figures 1A and IB; the Per fl sequence is from reference (12). Figure 4 shows the reactivity of ggtl 1 pl(13T) with anti-Deng I. Lysates from Y1089 lysogens induced for phage were reacted by dot-blot with rabbit anti-Per_r} 1 (Per p I) or normal rabbit serum (Nrs). Pots (2ml) were made in triplicate from lysates of bacteria infected with ggtl 1 pl(13T) (a) or ggtl 1 (b). When developed with 125i_.p ro tein A and autoradiography only the reaction between ggtl 1 pl(13T) lysate and the anti-Per p I showed reactivity. Figure 5 shows reaction of clone pGEX-pl(13T) with IgE in allergic serum. Overnight cultures of pGEX or pGEX-pl where diluted 1/10 in broth and grown for 2 hours at 37°C. They were induced with IPTG, grown for 2 hours at 37°C. The bacteria were pelletted and resuspended in PBS to 1/10 the volume of culture media. The bacteria were lysed by freeze/thaw and sonication. A radioimmune dot-blot was performed with 2ml of these lysates using mite-allergic or non-allergic serum. The dots in row 1 were from E, coli containing pGEX and row 2-4 from different cultures of E. coli infected with pGEX-pl(13T). Reactivity to pGEX-pl(13T) was found with IgE in allergic but not non-allergic serum. No reactivity to the vector control or with non-allergic serum was found. Figure 6 shows seroreactivity of cPNA clones coding for Per p II in plaque radioimmune assay. Segments of nitrocellulose filters from plaque lifts were taken from clones 1, 3, A, B and the vector control Ampl. These were reached by immunoassay for human IgE against allergic serum (AM) in row 1, non-allergic serum (WT) in row 2 and by protein A immunoassay for Per p I with rabbit antiserum in row 3. The clones 1, 3 and B reacted strongly with allergic serum but not non-allergic or vector control. (Clone B and vector control were not tested with non-allergic serum). Figures 7A and 7B show the nucleotide and predicted amino acid sequence of cPNA of ggtl 1 p II (Cl) (SEQ IP NOS: 3 and 4, respectively). Numbers to the right are nucleotide positions and numbers above are amino acid positions. Positive numbers for amino acids begin at the known N-terminal of Per p II and match the known sequence of the first 40 residues. Residues -1 to -16 resemble a typical leader sequence with a hydrophobic core. Figure 8 shows the N-terminal amino acid homology of Per p II and Per f II. (Per f II sequence from reference 30). Figure 9 is a restriction map of the cPNA insert of clone ggtl 1 f 1, including a schematic representation of the strategy of PNA sequencing. Arrows indicate directions in which sequences were read. Figures 10A and 10B are the nucleotide sequence and the predicted amino acid sequence of cPNA ggtl 1 f 1 (SEQ IP NOS: 5 and 6, respectively). Numbers above are nucleotide positions; numbers to the left are amino acid positions. Positive amino acid residue numbers correspond to the sequence of the mature excreted Per fl beginning with threonine. Negative sequence numbers refer to the signal peptide and the proenzyme regions of Dej_f I. The arrows indicate the beginning of the proenzyme sequence and the mature Per f I. respectively. The underlined residues -81 to -78 make up the proposed cleavage site for the proenzyme formation, while the underlined residues 53-55 represent a potential N-glycosylation site. The termination TGA codon and the adjacent polyadenylation signal are also underlined. Amino acid residues 1-28 correspond to a known tryptic peptide sequence determined by conventional amino acid sequencing analysis. Figure 1 1 is a composite alignment of the amino acid sequences of the mature Per p I (SEQ IP NO: 1 1) and Per fl proteins. The numbering above the sequence refers to Per p I. The asterisk denotes the gap that was introduced for maximal alignment. The symbol (.) is used to indicate that the amino acid residue of Per f I at that position is identical to the corresponding amino acid residue of Per p I. The arrows indicate those residues making up the active site of Per p I and Per f I. Figures 12A and 12 B are a comparison of the amino acid sequence in the pre- and pro-peptide regions of Per f I with those of rat cathepsin H, rat cathepsin L, papain. aleurain. CP1, CP2, rat cathepsin B, CTLA-2, MCP, Per p I and actinidin. Gaps, denoted by dashes, were added for maximal alignment. Pouble asterisks denote conserved amino acid residues which are shared by greater than 80% of the proenzymes: single asterisks show residues which are conserved in greater than 55% of the sequences. The symbol (.) is used to denote semiconserved equivalent amino acids which are shared by greater than 90% of the proenzyme regions. Figures 13A and 13B are a hydrophilicity plot of the Per p I mature protein and a hydrophilicity plot of the Per fl mature protein produced using the Hopp- Woods algorithm computed with the Mac Vector Sequence Analysis Software (IBI, New Haven) using a 6 residue window. Positive values indicate relative hydrophilicity and negative values indicating relative hydrophobicity. Figure 14 is the nucleotide sequence and the predicted amino acid sequence of Per f II cPNA (SEQ IP NOS: 7 and 8, respectively). Numbers to the right are nucleotide positions and numbers above are amino acid residues. The stop (TAA) signal is underlined. The first 8 nucleotides are from the oligonucleotide primer used to generate the cPNA, based on the Per p II sequence. Figure 15 is a restriction map of Per f II cPNA, which was generated by computer from the sequence data. A map of Per II similarly generated is shown for comparison. There are few common restriction enzyme sites conserved. Sites marked with an asterisk were introduced by cloning procedures. Figures 16A. 16B. and 16C show the alignment of Per f II and Per p II cPNA sequences. Numbers to the right are nucleotide position and numbers above are amino acid residues. The top line gives Per p II nucleotide sequence and the second the Per p II amino acid residues. The next two lines show differences of Per f II to these sequences. Figures 17A and 17B are hydrophilicity plots of Dsifll and Per p II using the Hopp-Woods algorithm computed with the Mac Vector Sequence Analysis Software (IBI, New Haven) using a 6-residue window. Figure 18 is a composite alignment of the amino acid sequences of five Per p I clones (a)-(e) which illustrates polymorphism in the Per p I protein (SEQ IP NO: 1 1 ). The numbering refers to the sequence of the Per p 1(a) clone. The symbol (- ) is used to indicate that the amino acid residue of a Per p I clone is identical to the corresponding amino acid residue of Per p 1(a) at that position. The amino acid sequences of these clones indicate that there may be significant variation in Per p I, with five polymorphic amino acid residues found in the five sequences. Figure 19 is a composite alignment of the amino acid sequences of three Per p II clones (c), ( 1 ) and (2) which illustrates polymorphism in the Per p II protein. The numbering refers to the sequence of the Per p 11(c) clone. The symbol (.) is used to indicate that the amino acid residue of a Per p II clone is identical to the correspondng amino acid residue of Per p II (c) at that position. Figure 20 is a composite alignment of the amino acid sequences of six Per f II clones (i.e.. pFLl, pFL2, MT3, MT5, MT18 and MT16) which illustrates polymorphism in the Per f ll protein (SEQ IP NO: 13). The numbering HEET * - ' - ■ refers to the sequences of the Per fpFLl clone. The symbol (.) is used to indicate that the amino acid residue of a Per f II clone is identical to the corresponding amino acid residue of Per f II pFLl at that position. Figures 21A. 21B. and 21 C are the nucleotide and predicted amino acid sequences of cPNA ggtl 1 pl(13T) (SEQ IP NOS: 9 and 10, respectively), including the full length of the preproenzyme form of Per p I. Negative sequence numbers refer to the proposed pre- and preproenzyme forms of Per p I. Petailed Pescription of the Invention The present invention relates to a nucleotide sequence coding for an allergen from the house dust mite Permatophagoides and to the encoded Permatophagoides protein or peptide which includes at least one epitope of the Permatophagoides allergen. It particularly relates to a nucleotide sequence capable of expression in an appropriate host of a major allergen of P. farinae. such as Per fl or -Der_f II, or of a peptide which includes at least one epitope of Per f I or of Der_f II. It also particularly relates to a nucleotide sequence capable of expression in an appropriate host of a major allergen of P. pteronyssinus- such as Per p I or Per p II, or of a peptide which includes at least one epitope of Per p I or of Per p II. The Permatophagoides nucleotide sequence is useful as a probe for identifying additional nucleotide sequences which hybridize to it and encode other mite allergens, particularly P. farinae or P. pteronyssinus allergens. Further, the present invention relates to nucleotide sequences which hybridize to a P. farinae protein-encoding nucleotide sequence or a P. pteronyssinus protein-encoding nucleotide sequence but which encode a protein from another species or type of house dust mite, such as P. microceras (e.g., Per m I and Per m II). The encoded Permatophagoides mite allergen or peptide which includes at least one Permatophagoides (Per f I or Per f II: Per p I or Per p II) epitope can be used for diagnostic purposes (e.g., as an antigen) and for therapeutic purposes (e.g., to desensitize an individual). Alternatively, the encoded house dust mite allergen can be a protein or peptide, such as a P. microceras protein or peptide, which displays the antigenicity of or is cross-reacitve with a Per f or a Per p allergen; generally, these have a high degree of amino acid homology. Accordingly, the present invention also relates to compositions which include a Permatophagoides allergen (e.g., Per fl allergen, Per f II allergen; Per p I or Per p II allergen or other _D_, allergen cross-reactive therewith) or a peptide which includes at least one epitope of a Permatophagoides allergen (Per fl. Per f II, Per p I, Per p II or other EX allergen cross-reactive therewith) individually or in combination, and which can be used for therapeutic applications (e.g., desensitization). As is described below, PNA coding for major allergens from house dust mites have been isolated and sequenced. In particular, and as is described in greater detail in the Examples, cPNA clones coding for the Per p I, Per p II, Per f I and Per f II allergens have been isolated and sequenced. The nucleotide sequence of each of these clones has been compared with that of the homologous allergen from the related mite species (i.e., Per p I and Per f l: Per p II and Per f II). as has the predicted amino acid sequence of each. The following is a description of isolation and sequencing of the two cPNA clones coding for Penf allergens and their comparison with the corresponding P. pteronyssinus allergen and a description of use of the nucleotide sequences and encoded products in a diagnostic or a therapeutic context. Isolation and Sequence Analysis of Per f I A cPNA clone coding for Per fl. a major allergen from the house dust mite P. farinae. has been isolated and sequenced. A restriction map of the cPNA insert of the clone is represented in Figure 9, as is the strategy of PNA sequencing. This Per fl cPNA clone contains a 1.1 -kb cPNA insert encoding a typical signal peptide, a proenzyme region and the mature Per fl protein. The product is 321 amino acid residues; a putative 18 residue signal peptide, an 80 residue proenzyme (pro- peptide) region, and a 223 residue mature enzyme region. The derived molecular weight is 25,191. The nucleotide sequence and the predicted amino acid sequence of the Per fl cPNA are represented in Figures 10A and 10B. The deduced amino acid sequence shows significant homology to other cysteine proteases in the pro-region, as well as in the mature protein. Sequence alignment of the mature Per fl protein with the homologous allergen Per p I from the related mite P. pteronyssinus (Figure 1 1) revealed a high degree of homology (81%) between the two proteins, as predicted by previous sequencing at the protein level. In particular, the residues comprising the active site of these enzymes were conserved and a potential N-glycosylation site was present at equivalent positions in both mite allergens. Conserved cysteine residue pairs (31, 71) and (65, 103), where the numbering refers to Per p I. are apparently involved in disulphide bond formation on the basis of the assumed similarity of the three dimensional structure of Per p I and Per f I to that of papain and actinidin, which also have an additional disulphide bridge! The fifth and final cysteine residue for which there is a homologous cysteine residue in papain and actinidin is the active site cysteine (residue 35 in Per fl). It is not unlikely that the two extra cysteine residues present in Per p I and Per fl may be involved in forming a third disulphide bridge. ; 1 1 v r. s s The potential N-glycosylation site in Per p I is also present at the equivalent position in Per f I. with conservation of the crucial first and last residues of the tripeptide site. The degree of of Per f I and Per p I has yet to be determined. Carbohydrates, including mannose, galactose, N-acetylglucosamine and N-acetylgalactosamine, have been reported in purified preparations of these mite allergens (Chapman, M.P., J. Immunol.. 125:587- 592 (1980); Wolden, S. e al., Int. Arch. Allergy Appl. Immunol.. £8 l44-151 (1982)). Given the degree of homology over the first thirty N-terminal amino acid residues between mature Per p I and Per m I (70%) and mature Per fl and Per I (97%>) with the Per m I residues determined by conventional amino acid sequencing (Platts-Mills TAE £ aL, In: Mite Allergy, a World-Wide Problem. 27-29 (1988); Lind, P. and N. Horn, In: Mite Allergy, a World-Wide Problem. 30-34 (1988)), it is probable that the full mature Per m I sequence will confirm an overall 70-80% homology between the Group I mite allergens. Per m I is an allergen from H. microceras. High homology between the proenzyme moieties of Per p I and Per fl (91%>) over the residues -23 to -1 and the structural analysis of Per f I suggests that the Group I allergens are likely to have N-terminal extension peptides of the mature protein of homologous structure and, at least for the pro-peptide, composition. Studies on the fine structure of the design of signal sequences have identified three structurally dissimilar regions so far: a positively charged N-terminal (n) region, a central hydrophobic (h) region and a more polar C-terminal (c) region that seems to define the cleavage site (Von Heijne, G., EMBO J.. 2:2315-2323 (1984); Eur. J. Biochem.. 121: 17-21 (1983); J. Mol. Biol.. 1£4:99-105 (1985)). Analysis of the signal peptide of Per f I revealed that it, too, contained these regions (Figures 12A and 12B). The n-region is extremely variable in length and composition, but its net charge does not vary appreciably with the overall length, and has a mean value of about +1.7. The n-region of the Per f l signal peptide, with a length of two residues, has a net charge of +2 contributed by the initiator methionine (which is unformylated and hence positively charged in eukaryotes) and the adjacent lysine (Lys) residue. The h-region of Per f I is enriched with hydrophobic residues, the characteristic feature of this region, with only one hydrophilic residue serine (Ser) present which can be tolerated. The overall amino acid composition of the Per f l c-region is more polar than that of the h-region as is found in signal sequences with the h/c boundary located between residues -6 and -5, which is its mean position in eukaryotes. Thus, the Per fl pre-peptide sequence appears to fulfill the requirements to which a functional signal sequence must conform. While the signal sequence of Per f I and other cysteine proteases share structural homology, all being composed of the n,h and c-regions, they are highly variable with respect to overall length and amino acid sequence, as is clear in Figures 12A and 12B. However, significant sequence homology has been shown between the pro-regions of cysteine protease precursors (Ishidoh, K. et al.. FEBS Letters. 226:33- 37 (1987)). Alignment of the proenzyme regions of Per f I and a number of other cysteine proteases (Figures 12A and 12B) indicated that these proregions share a number of very conserved residues as well as semi-conserved residues which were present in over half of the sequences. This homology was increased if conservative amino acids such as valine (Val), isoleucine (He) and leucine (Leu) (small hydrophobic residues) or arginine (Arg) and Lys (positively charged residues) were regarded as identical. The Per fl proregion possessed six out of seven highly conserved amino acids and all the residues at sites of conservative changes. The homology at less conserved sites was lower. Homology in the pro-peptide, in particular the highly conserved residues, may be important when considering the function of the pro-peptide in the processing of these enzymes, since it indicates that these sequences probably have structural and functional similarities. Highly cross-reactive B cell epitopes on J___S £ I and Per p I have been demonstrated using antibodies present in mouse, rabbit and human sera (Heymann, P.W. et al.. J. Immunol. 117:2841-2847 (1986); Platts-Mills, TAE et al.. J. Allergy Clin. Immunol. 1^:398-407 (1986)). However, species-specific epitopes have also been defined in these systems. Murine monoclonal antibodies bound predominantly to species-specific determinants (Platts-Mills TAE et al.. J. Allergy Clin. Immunol. _U9_: 1479-1484 (1987)). Some 40% of rabbit anti-Der rj I reactivity was accounted for by epitopes unique to Per p I (Platts-Mills, TAE et al.. JL Allergy Clin. Immunol. 78:398-407 (1986)), and some species-specific binding of antibodies from allergic humans was observed, although the majority bind to cross- reactive epitopes (Platts-Mills TAE et al.. J. Immunol. 139:1479-1484 (1987)). The recombinant PNA strategy of gene fragmentation and expression was used (Greene, W.K. et al., Immunol. (1990)) to define five antigenic regions of recombinant Per p I which contained B cell epitopes recognized by a rabbit anti-]Der_p I antiserum. Using the technique of immunoabsorption, three of these putative epitopes were shown to be shared with Per f I (located on regions containing amino acid residues 34-47, 60-72 and 166-194) while two appeared to be specific for Per p I (regions 82-99 and 112-140). Pifferences in the reactivity of these peptides to rabbit anti-P. farinae supported the above division into cross-reactive and species-specific epitopes. The sequence differences shown between the Per p I and the Der f I proteins are primarily located in the N and C terminal regions, as well as in an extended surface loop (residues 85-136) linking the two domains of the enzyme that includes helix P (residues 127-136), as predicted from the secondary and tertiary structures of papain and actinidin (Baker, E.N. and J. Prenth, In: Biological Macromolecules and Assemblies. Vol. 3, pp. 314-368, John Wiley and Sons, NY (1987)). The surface location of these residues is supported by the hydrophilicity plots of Per p I and Per fl in Figures 13A and 13B, which illustrate the predominantly hydrophilic nature of this region that predicts surface exposure. This region also contains the two species-specific B cell epitopes recognized by the rabbit anti-Per p I serum (see above). Analysis of the sequences in the regions containing the cross-reactive epitopes (located in regions 34-47 and 60-72) are completely conserved between Per p I and Per fl. while the majority of residues in a third cross- reactive epitope-containing region (residues region 166-194) were conserved. Expression of cPNA encoding Per fl results in production of pre- pro-Per f I protein in R coli. a recombinant protein of greater solubility, stability and antigenicity than that of recombinant Per p I. Protein encoded by Per fl cPNA has been expressed using a pGEX vector and has been shown by radioimmune assay to react with rabbit anti-P. farinae antibodies. The availability of high yields of soluble Per f l allergen and antigenic derivatives will facilitate the development of diagnostic and therapeutic agents and the mapping of B and T cell antigenic determinants. With the availability of the complete amino acid sequence of recombinant PerjT, mapping of the epitopes recognized by both the B and T cell compartments of the immune system can be carried out. The use of techniques such as the screening of overlapping synthetic peptides, the use of monoclonal antibodies and gene fragmentation and expression should enable the identification of both the continuous and topographical epitopes of Per f I. It will be particularly useful to determine whether allergenic (IgE-binding) determinants have common features and are intrinsically different from antigenic (IgG-binding) determinants and whether T cells recognize unique epitopes different from those recognized by B cells. Studies to identify the Per fl epitopes reactive with mite allergic human IgE antibodies and the division of these into determinants cross- reactive with Per p I and determinants unique to Per fl can also be carried out. B cell (and T cell) epitopes specific for either species can be used to provide useful diagnostic reagents for determining reactivity to the different mite species, while cross-reacting epitopes are candidates for a common immunotherapeutic agent. As described in detail in the Examples, a cPNA clone coding for Per p I which contained a 0.8-kb cPNA insert has been isolated. Sequence analysis revealed that the 222 amino acid residue mature recombinant Per p I protein showed significant homology with a group of cysteine proteases, including actinidin, papain, cathepsin H and cathepsin B. Isolation and Sequence Analysis of Per f II A cPNA clone coding for Per f II. a major allergen from the house dust mite P. farinae. has been isolated and sequenced, as described in the Examples. The nucleotide sequence and the predicted amino acid sequence of the Per f II cPNA are represented in Figure 14. A restriction map of the cPNA insert of a clone coding for Per f II is represented in Figure 15. Figures 16A, 16B, and 16C show the alignment of DexfH and Per p II cPNA sequences. The homology of the sequence of Deri " II with Per p II (88%) is higher than the 81% homology found with Per p I and Per f I. which is significantly different (p<0.05) using the chi2 distribution. The reason for this may simply be that the Group I allergens are larger and each residue may be less critical for the structure and function of the molecule. It is known, for example, that assuming they adopt a similar conformation to other cysteine proteases, many of the amino acid differences in Per p I and Per fl lie in residues linking the two domain structures of the molecules. The 6 cysteine molecules are conserved between the group II allergens, suggesting a similar disulphide bonding, although this may be expected, given the high overall homology. Another indication of the conservation of these proteins is that 34/55 of the nucleotide changes of the coding sequence are in the third base of a codon, which usually does not change the amino acid. Residues that may be of importance in the function of the molecule are Ser 57 where all three bases are changed but the amino acid is conserved. A similar phenomenon exists at residue 88, where a complete codon change has conserved a small aliphatic residue. Again, like Per p II, the Per f II cPNA clone does not have a poly A tail, although the 3' non-coding region is rich in adenosine and has two possible polyadenylation signals ATAA. The nucleotides encoding the first four residues are from the PCR primer which was designed from the known homology of Per p II and Per f II from N-terminal amino acid sequencing. A primer based on the C-terminal sequence can now be used to determine these bases, as well as the signal sequence. Uses of the subject allergenic proteins/peptides and PNA encoding same The materials resulting from the work described herein, as well as compositions containing these materials, can be used in methods of diagnosing, treating and preventing allergic responses to mite allergens, particularly to mites of the genus Permatophagoides. such as P. farinae and P. pteronyssinus. In addition, the cPNA (or the mRNA from which it was transcribed) can be used to identify other similar sequences. This can be carried out, for example, under conditions of low stringency and those sequences having sufficient homology (generally greater than 40%) can be selected for further assessment using the method described herein. Alternatively, high stringency conditions can be used. In this manner, PNA of the present invention can be used to identify sequences coding for mite allergens having amino acid sequences similar to that of Per f I, Per f II, Per p I or Per p II. Thus, the present invention includes not only P. farinae and P. pteronyssinus allergens, but other mite allergens as well (e.g., other mite allergens encoded by PNA which hybridizes to PNA of the present invention). Proteins or peptides encoded by the cPNA of the present invention can be used, for example, as "purified" allergens. Such purified allergens are useful in the standardization of allergen extracts or preparations which can be used as reagents for the diagnosis and treatment of allergy to house dust mites. Through use of the peptides of the present invention, allergen preparations of consistent, well-defined composition and biological activity can be made and administered for therapeutic purposes (e.g., to modify the allergic response of a house dust mite-sensitive individual). Per fl or Dsr- II peptides or proteins (or modified versions thereof, such as are described below) may, for example, modify B-cell response to Denfl or βejlf II, T-cell response to Der_f I and Dsr_ II, or both responses. Similarly, Per p I or Per p II proteins or peptides may be used to modify B-cell and or T-cell response to Per p I or Per p II. Purified allergens can also be used to study the mechanism of immunotherapy of allergy to house dust mites, particularly to Per fl. Per f II. Per p I and Per p II, and to design modified derivatives or analogues which are more useful in immunotherapy than are the unmodified ("naturally-occurring") peptides. In those instances in which there are epitopes which are cross- reactive, such as the three epitopes described herein which are shared by Per fl and Per p I, the area(s) of the molecule which contain the cross-reactive epitopes can be used as common immunotherapeutic peptides to be administered in treating allergy to the two (or more) mite species which share the epitope. For example, the cross-reactive epitopes could be used to induce IgG blocking antibody against both allergens (e.g., Per fl and Per p I allergen). A peptide containing a univalent antibody epitope can be used, rather than the entire molecule, and may prove advantageous because the univalent antibody epitope cannot crosslink mast cells and cause adverse reactions during desensitizing treatments. It is also possible to attach a B cell epitope to a carrier molecule to direct T cell control of allergic responses. Alternatively, it may be desirable or necessary to have peptides which are specific to a selected Permatophagoides allergen. As described herein, two epitopes which are apparently Per p I-specific have been identified. A similar approach can be used to identify other species-specific epitopes (e.g., Per p I or II, Dsr_f I or II). The presence in an individual of antibodies to the species-specific epitopes can be used as a quick serological test to determine which mite species is causing the allergic response. This would make it possible to specifically target therapy provided to an individual to the causative species and, thus, enhance the therapeutic effect. Work by others has shown that high doses of allergens generally produce the best results (i.e., best symptom relief). However, many people are unable to tolerate large doses of allergens because of allergic reactions to the allergens. Modification of naturally-occurring allergens can be designed in such a manner that modified peptides or modified allergens which have the same or enhanced therapeutic properties as the corresponding naturally-occurring allergen but have reduced side effects (especially anaphylactic reactions) can be produced. These can be, for example, a peptide of the present invention (e.g., one having all or a portion of the amino acid sequence of Per fl or Dsr_fII, Per p I or Per p II). Alternatively, a combination of peptides can be administered. A modified peptide or peptide analogue (e.g., a peptide in which the amino acid sequence has been altered to modify immunogenicity and/or reduce allergenicity or to which a component has been added for the same purpose) can be used for desensitization therapy. Administration of the peptides of the present invention to an individual to be desensitized can be carried out using known techniques. A peptide or combination of different peptides can be administered to an individual in a composition which includes, for example, an appropriate buffer, a carrier and/or an adjuvant. Such compositions will generally be administered by injection, inhalation, transdermal application or rectal administration. Using the information now available, it is possible to design a Per I, Per p II, Per fl or Dsr_f II peptide which, when administered to a sensitive individual in sufficient quantities, will modify the individual's allergic response to Per p I, Per p II, Per f I and/or Per f II. This can be done, for example, by examining the structures of these allergens, producing peptides to be examined for their ability to influence B- cell and/or T-cell responses in house dust mite-sensitive individuals and selecting appropriate epitopes recognized by the cells. Synthetic amino acid sequences which mimic those of the epitopes and which are capable of down regulating allergic response to Per p I, Per p II, Per fl or Per f II allergens can be made. Proteins, peptides or antibodies of the present invention can also be used, in known methods, for detecting and diagnosing allergic response to Per fl or Per f II. For example, this can be done by combining blood obtained from an individual to be assessed for sensitivity to one of these allergens with an isolated allergenic peptide of house dust mite, under conditions appropriate for binding of or stimulating components (e.g., antibodies, T cells, B cells) in the blood with the peptide and determining the extent to which such binding occurs. _______χ_£ and Per p proteins or peptides can be administered together to treat an individual sensitive to both allergen types. It is now also possible to design an agent or a drug capable of blocking or inhibiting the ability of Per p I, Per p II, Per fl or Per f II to induce an allergic reaction in house dust mite-sensitive individuals. Such agents could be designed, for example, in such a manner that they would bind to relevant anti- Per p I, anti-βfi p II, anti-Denf I or anti-Deiif II IgEs, thus preventing IgE- allergen binding and subsequent mast cell degranulation. Alternatively, such agents could bind to cellular components of the immune system, resulting in suppression or desensitization of the allergic response to these allergens. A non- restrictive example of this is the use of appropriate B- and T-cell epitope peptides, or modifications thereof, based on the cPNA/protein structures of the present invention to suppress the allergic response to these allergens. This can be carried out by defining the structures of B- and T-cell epitope peptides which affect B- and T-cell function in in vitro studies with blood cells from house dust mite- sensitive individuals. The cPNA encoding Per p I, Per p II, Per fl or Per f II or a peptide including at least one epitope thereof can be used to produce additional peptides, using known techniques such as gene cloning. A method of producing a protein or a peptide of the present invention can include, for example, culturing a host cell containing an expression vector which, in turn, contains PNA encoding all or a portion of a selected allergenic protein or peptide (e.g., Per p I, Per p II, Per f I. Bfinf II or a peptide including at least one epitope). Cells are cultured under conditions appropriate for expression of the PNA insert (production of the encoded protein or peptide). The expressed product is then recovered, using known techniques. Alternatively, the allergen or portion thereof can be synthesized using known mechanical or chemical techniques. As used herein, the term protein or peptide refers to proteins or peptides made by any of these techniques. The resulting peptide can, in turn, be used as described previously. PNA to be used in any embodiment of this invention can be cPNA obtained as described herein or, alternatively, can be any oligodeoxynucleotide sequence having all or a portion of the sequence represented in Figures 1A and IB, 7A and 7B, 10A and 10B, and 14 or their functional equivalent. Such oligodeoxynucleotide sequences can be produced chemically or mechanically, using known techniques. A functional equivalent of an oligonucleotide sequence is one which is capable of hybridizing to a complementary oligonucleotide sequence to which the sequence (or corresponding sequence portions) of Figures 1A and IB, 7A and 7B, 10A and 10B, and 14 hybridizes and/or which encodes a product (e.g., a polypeptide or peptide) having the same functional characteristics of the product encoded by the sequence (or corresponding sequence portion) represented in these figures. Whether a functional equivalent must meet one or both criteria will depend on its use (e.g., if it is to be used only as an oligoprobe, it need meet only the first criterion and if it is to be used to produce house dust mite allergen, it need only meet the second criterion). The structural information now available (e.g., PNA, protein/peptide sequences) can also be used to identify or define T cell epitope peptides and/or B cell epitope peptides which are of importance in allergic reactions to house dust mite allergens and to elucidate the mediators or mechanisms (e.g., interleukin-2, interleukin-4, gamma interferon) by which these reactions occur. This knowledge should make it possible to design peptide-based house dust mite therapeutic agents or drugs which can be used to modulate these responses. The present invention will now be further illustrated by the following Examples, which are not intended to be limiting in any way. EXAMPLE 1 MATERIALS ANP METHOPS Cloning and Expression of Per p I cPNA. Polyadenylated mRNA was isolated from the mite Permatophagoides pteronyssinus cultured by Commonwealth Serum Laboratories, Parkville, Australia, and cPNA was synthesized by the RNA-ase H method (5) using a kit (Amersham, International, Bucks). After the addition of EcoRI linkers the cPNA was ligated into ggtl 1 and plated in . £θli Y1090 (r-) (Promega Biotec, Madison, Wisconsin), to produce a library of 5x10^ recombinants. Screening was performed by plaque radioimmune assay (6) using a rabbit anti-Per p I antiserum (7). Reactivity was detected by hydrochloride in 0.1 M sodium acetate buffer pH 5.2 were then added and the mixture was homogenized and spun at 10,000 rpm for 30 min in a Sorval SS34 rotor. The supernatant was collected and layered onto a CsCl pad (5ml of 4.8 M CsCl in 10 mM EPTA) and centrifuged at 37,000 rpm for 16h at 15°C in a SW41 TI rotor (Beckman Instruments, Inc., Fullerton, CA). The PNA band at the interphase was collected and diluted 1 :15 in lOmM Tris HCl/1 mM EPTA buffer, pH 8.0. Banding of genomic PNA in CsCl was carried out by the standard method. Isolation of PNA from ggtl 1 pi cPNA Clone. Phage PNA from ggtl 1 pi clone was prepared by a rapid isolation procedure. Clarified phage plate lysate (1 ml) was mixed with 270ml of 25% wt/vol polyethylene gly col (PEG 6000) in 2.5 M NaCl and incubated at room temperature for 15 min. The mixture was then spun for 5 min in a microfuge (Eppendorf, Federal Republic of Germany), and the supernatant was removed. The pellet was dissolved in 100 ml of 10 mM Tris/HCl pH 8.0 containing 1 mM EPTA and 100 mM NaCl. This PNA preparation was extracted 3 times with phenol/chloroform (1:1) and the PNA was precipitated by ethanol. PNA Hybridization. Nucleic acid was radiolabelled with 32p y nick translation (10). PNA samples were digested with appropriate restriction enzymes using conditions recommended by the supplier. Southern blots were prepared using Zeta-Probe membranes (Bio-Rad Laboratories, Richmond, CA). Prehybridization, hybridization, posthybridization washes were carried out according to the manufacturers recommendations (bulletin 1234, Bio-Rad Laboratories). Cloning and DNA Seguencing To clone the 0.8-kb cDNA insert from clone ggtl 1 pi into plasmid pUC8, phage DNA was digested with EcoRI restriction enzyme and then ligated to EcoRI-digested pUC8 DNA and used to transform Escherichia coli JM83. The resulting recombinant plasmid was designated as pHDM 1. To obtain clones for DNA sequence analysis, the cDNA insert was isolated from pHDM 1 and ligated to M13-derived sequencing vectors mpl8 and mpl9 (16). Transformation was carried out using E. £θli JM107 and sequencing was performed by the dideoxynucleotide chain termination method (11). RESULTS Several phage clones reacted with the rabbit anti Der p I serum and hybridized with all 3 oligonucleotide probes. One of these, ggtl 1 pl(13T), was examined further. The nucleotide sequence of the cDNA insert from this clone, ggtl 1 pi, was determined using the sequencing strategy shown in Fig. 2. The complete sequence was shown to be 857 bases long and included a 69-base-long 5' proximal end sequence, a coding region for the entire native Der p I protein of 222 amino acids with a derived molecular weight of 25,371, an 89-base-long 3' noncoding region and a poly (A) tail of 33 residues (Figures 1A and IB). The assignment of a threonine residue at position 1 as the NH2- terminal amino acid of Der p I was based on data obtained by NH2-terminal amino acid sequencing of the pure protein isolated from mite excretions (17). The predicted amino acid sequence matched with data obtained by amino acid sequence analysis of the NH2-terminal region as well as with internal sequences derived from analyses of tryptic peptides (Figures 1A and IB). The complete mature protein is coded by a single open reading frame terminating at the TAA stop codon at nucleotide position 736-738. At present, it is not certain whether the first ATG codon at nucleotide position 16-18 is the translation initiation site, since the immediate flanking sequence of this ATG codon (TTGATGA) showed no homology with the Kozak consenses sequence (ACCATGG) for the eukaryotic translation initiation sites (18). In addition, the 5' proximal end sequence does not code for a typical signal peptide sequence (see below). The amino acid sequence predicted by nucleotide analysis is shown in Figures 1 A and IB. A protein data-base search revealed that the Der p I amino acid sequence showed homology with a group of cysteine proteases. Previous cDNA studies have shown that lysosomal cathepsins B, a mouse macrophage protease and a cysteine protease from an amoeba have transient pre- and proform intermediates (19-21), and inspection of the amino acid sequence at the 5' proximal end of the ggtl 1 pi cDNA clone suggests that Der p I may be similar. First, the hydrophilicity plot (22) of the sequence preceding the mature protein sequence lacks the characteristic hydrophobic region of a signal peptide (23) and second, an Ala-X-Ala sequence, the most frequent sequence preceding the signal peptidase cleavage site (24,25), is present at positions -13, -14, -15 (Figures 1A and IB). Therefore, it is proposed that cleavage between pro-Der p I sequence and the pre- Der p I sequence occurs between Ala (-13) and Phe (-12). Thus, pro-Der p I sequence begins at residues Phe (-12) and ends at residues Glu (-1). The amino acids residues numbered -13 to -23 would then correspond to a partial signal peptide sequence. The full length of the Der p I preproenzyme sequence has been determined and is shown in Figures 21 A and 2 IB. The negative sequence numbers refer to the pre- and preproenzyme forms of Der p I. When the 857-bp cDNA insert was radiolabelled and hybridized against a Southern blot of EcoRI-digested genomic DNA from house dust mite, hybridization to bands of 1.5, 0.5, and 0.35 kb was observed (data not shown). As shown in the restriction enzyme map of the cDNA insert (Figure 2), there was no internal EcoRI site and the multiple hybridization bands observed suggest that Der p I is coded by a noncontiguous gene. The results also showed little evidence of gene duplication since hybridization was restricted to fragments with a total length of 2.4 kb. The N-terminal can be compared with N-terminal of the equivalent protein from D.farinae (Der f I) (12). There is identity in 11/20 positions of the sequences available for comparison (Fig. 3). To examine the protein produced by ggtl 1 pl(13T), phage was lysogenized in Y1089 (r-) and the bacteria grown in broth culture at 30°C. Phage was induced by temperature switch and isopropyl thiogalactopyranoside (IPTG) (6) and the bacteria were suspended in PBS to 1/20 of the culture volume, and sonicated for an antigen preparation. When examined by 7.5% SDS-PAGE electrophoresis it was found that ggtl 1 pl(13T) did not produce a Mr 116K β- galactosidase band but instead produced a 140K band consistent with a fusion protein with the Der p I contributing a 24kDa moiety (6). Rabbit anti Der p I was shown to react with the lysate from ggtl 1 pl(13T) (Fig. 4). EXAMPLE 2 Expression of Der p I cDNA products reactive with IgE from allergic serum. The DNA insert from ggtl 1 pl(13T) which codes for Der p I was subcloned into the EcoRI site of the plasmid expression vector (pGEX)(26) where it could be expressed as a fusion with a glutathione transferase molecule. E coli infected with this plasmid pGEX-pl(13T) or with the vector alone were grown to a log phase culture and harvested by centrifugation. The bacteria were suspended in PBS to 1/20 of their culture volume and lysed by freeze- thawing. The lysate was shown by sodium dodecyl- sulphate polyacrylamide electrophoresis to express a fusion protein in high concentration of the expected Mr 50,000. These lysates were then tested for their ability to react with IgE from allergic serum by radioimmune dot-blot conducted by the method described by Thomas and Rossi (27). The serum was taken from donors known to be mite-allergic or from non- allergic controls. Reactivity was developed by 125ι_ monoc ι ona ι anti-IgE and autoradiography. Figure 5 shows the lysate from pGEX-pl(13T), but not the vector control reacted with IgE in allergic serum, but not non allergic serum. EXAMPLE 3 Inhibition of IgE antibody responses to Der p I by treatment with the product from a cDNA clone coding for Der p I. E_. coli lysogenized by ggtl 1 pl(13T) were grown and induced by temperature switch to produce a recombinant fusion protein which was consistent with a 24 kD Der p I moiety and a 116 kP β-galactosidase moiety (pl(13T) (28). This protein was mostly insoluble and could be isolated to about 90% purity, judged by sodium didodecyl polyacrylamide electrophoresis, by differential centrifugation. A similar protein was produced from another gtl 1 cPNA mite clone ggt pX (2c). To test for the ability of the recombinant protein to modify IgE antibody responses to Per p I, groups of 4-5 CBA mice were injected intraperitoneally with 2 mg of the pl(13T) or pX (2c) fusion proteins and after 2 days given a subcutaneous injection of 5mg of native Per p I (from mite culture medium) in aluminium hydroxide gel. The IgE antibody titres were measured by passive cutaneous anaphylaxis (PCA) after 3 and 6 weeks. The methods and background data for these responses have been described by Stewart and Holt (29). For a specificity control, groups of mice injected with pl(13T) or pX (2c) were also injected with lOmg of ovalbumin in alum. Responses were compared to mice without prior pl(13T) or pX (2c) treatment (Table 1). After 3 weeks mice either not given an injection of recombinant protein or injected with the control pX (2c) had detectable anti Per p I PCA titres (1/2 or greater). Only 1/5 of mice treated with recombinant pl(13T) had a detectable titre and this at 1/4 was lower than all of the titres of both control groups. Titres of all groups at 6 weeks were low or absent (not shown). The PCA response to ovalbumin was not significantly affected by treatment with recombinant proteins. These data show the potential of the recombinant proteins to specifically decrease IgE responses as required for a desensitizing agent. TABLE 1 Inhibition of anti-Per p I IgE by preinjection with with recombinant Per p I. preinjection immunizing IgE (PCA titres at d21 group -2 days injection (dO) (5mg/alum) responders titres 1 - Per p I 4/4 1/16-1/64 2 pX(2C) Per p I 5/5 1/8-1/16 3 pl(13T) Per p i 1/5* 1/4* 4 - ovalbumin 4/4 1/64-1/256 5 pX(2C) ovalbumin 5/5 1/32-1/128 6 pl(13T) ovalbumin 5/5 1/64-1/256 Mice were given a preinjection on day -2 and then immunized with Per p I or ovalbumin on day 0. Serum antibody titres were measured on day 21 and 42 by PCA in rat skin. Significant anti-D£ £ I titres were not detected on day 42 (not shown). The PCA were measured to Per p I for groups 1-3 and ovalbumin for groups 4-6. The anti-Per p I titres were lower (p<0.001)* when pretreated with recombinant Per p I pl(13T). "Mann Whitney analysis. EXAMPLE 4 Expression of Per p I antigenic determinants by fragments of the cPNA from ggtl 1 plfl3 ) The cPNA from ggtl 1 (13T) coding for Per p I was fragmented by sonication. The fragments (in varying size ranges) were isolated by electrophoresis. filled in by the Klenow reaction to create blunt ends. EcoRI linkers were attached and the fragment libraries cloned in ggtl 1. The methods used for the fragments cloning were the same as that used for cPNA cloning (6). Plaque immunoassay was used for screening with rabbit anti-Per p I. Three phage clones reacting with the antiserum were isolated and the oligonucleotide sequences of the cloned fragments obtained. Two of these were found to code for Per p I amino acids 17-55 (see Figures 1A and IB for numbering) and one for amino acids 70-100. Such fragments will eventually be useful for both diagnostic reagents to SUBSTIT K-- : r- 's s determine epitope reactivity and for therapy where molecules of limited allergenicity may increase safety of desensitisation. EXAMPLE 5 Cloning and expression of cPNA coding for the major mite allergen Per p IT. The Permatophagoides pteronyssinus cPNA library in ggtl 1 previously described was screened by plaque radioimmune assay using nitrocellulose lifts (6). Instead of using specific antisera the sera used was from a person allergic to house dust mites. The serum (at 1/2 dilution) was absorbed with I . coli. To detect reactivity an *25j labelled monoclonal anti-IgE was used (at 30ng/ml with 2x10^ cpm/ml (approx. 30% counting efficiency)). After 1 hour the filters were washed and autoradiography performed. Using this procedure 4 clones reacting with human IgE were isolated. It was found they were related by PNA hybridization and had an identical pattern of reactivity against a panel of allergic sera. Fig. 6 shows IgE reactivity in plaque radioimmunoassay against allergic serum (AM) (top row) or non allergic (WT). Here, clones 1, 3 and 8 react strongly, but only against allergic sera. The amp 1 segments (present in row 1) are a ggtl 1 vector control. The bottom row is an immunoassay with rabbit anti- Per p I, developed by 25j staphylococcus protein A which shows no significant reactivity. The clones were tested against a panel of sera. Serum from five patients without allergy to mite did not react, but serum from 14/17 people with mite allergy showed reactivity. The PNA insert from the clone ggtl 1 pII(Cl) was subcloned into Ml 3 mpl8 and Ml 3 mpl9 and sequenced by the chain termination method. The nucleotide sequence (Figures 7A and 7B) showed this allergen was Per p II by (a) the homology of the inferred amino acid sequence of residues 1-40 with that of the N-terminal amino acid of Per p II (30); and (b) the homology of this sequence with the equivalent Per f II allergen from Permatophagoides farinae (30). EXAMPLE 6 Isolation and Characterization of cPNA Coding for Per f I MATERIALS ANP METHOPS Permatophagoides farinae culture Mites were purchased from Commonwealth Serum Laboratories, Parkville, Australia. Construction of the P. farinae cPNA ggtl 1 library Polyadenylated mRNA was isolated from live P. farinae mites and cPNA was synthesized by the RNase H method (Gubler, V. and B.J. Hoffman, Gene 21:263-269 (1983)) using a kit (Amersham International, Bucks.). After the addition of EcoRI linkers (New England Biolabs, Beverly, MA) the cPNA was ligated to alkaline phosphatase treated ggtl 1 arms (Promega, Madison, WI). The ligated PNA was packaged and plated in E. coli Y1090 (r-) to produce a library of 2x10^ recombinants. Isolation of Per f I cPNA clones from the P. farinae cPNA ggtl 1 library Screening of the library was performed by hybridization with two probes comprising the two Per p I cPNA BamHI fragments 1-348 and 349-857 generated by BamHI digestion of a derivative of the Per p I cPNA which has had two BamHI restriction sites inserted between amino acid residues -1 and 1 and between residues 116 and 117 by site-directed mutagenesis (Chua, K.Y. et al.. J. Exp. Med. 16J:175-182 (1988)). The probes were radiolabelled with 32p by nick translation. Phage were plated at 20,000 pfu per 150mm petri dish and plaques were lifted onto nitrocellulose (Schleicher and Schull, Passel, FRG), denatured and baked (Maniatis, T. et al.. Molecular Cloning: Laboratory anual. Cold Spring Harbor Laboratory Press (1982)). Prehybridizations were performed for 2 hours at 42°C in 50% formamide/5 x SSCE/1 x Penhardt's/poly C (O.lmg/miypoly U(0.1mg/ml) with hybridization overnight at 42°C at 10 6 cpm/ml. Post hybridization washes consisted of 15 min washes at room temperature with 2 x sodium chloride citrate (SSC)/0.1% sodium dodecylsulphate (SPS), 0.5 x SSC/0.1 % SPS, 0.1 x SSC/0.1 % SPS successively and a final wash at 50°C for 30 min in 0.1 x SSC/1% SPS. Isolation of PNA from ggtl 1 f 1 cPNA clones - Phage PNA from ggtl 1 f 1 clones was prepared by a rapid isolation procedure. Clarified phage plate lysate (1 ml) was mixed with 270 of 25% wt/vol polyethylene glycol (PEG 6000) in 2.5M NaCl and incubated at room temperature for 15 min. The mixture was then spun for 5 min in a microfuge (Eppendorf, FRG), and the supernatant was removed. The pellet was dissolved in 100 mL of lOmM Tris/HCl pH8.0 containing 1 mM EPTA and 100 mM NaCl (TE). This PNA preparation was extracted with phenol TE, the phenol phase was washed with 100 mP TE, the pooled aqueous phases were then extracted another 2 times with phenol TE, 2 times with Leder phenol (phenol chloroform isoamylalcohol; 25:24:1), once with chloroform and the PNA was precipitated by ethanol. PNA sequencing To obtain clones for PNA sequence analysis, the ggtl 1 fl phage PNA was digested with EcoRI restriction enzyme (Pharmacia, Uppsala, Sweden) and the PNA insert was ligated to EcoRI-digested M13-derived sequencing vectors mp 18 and mp 19 (Maniatis, T. et al.. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1982)). Transformation was carried out using E. coli TG-1 and sequencing was performed by the dideoxynucleotide chain termination method (Sanger, F. et al., Proc. Natl. Acad. Sci. USA. 24:5463-5467 (1977)) using the Sequenase version 2.0 DNA sequencing kit (U.S.B., Cleveland, Ohio). Polymerase chain reaction (?CK) PCR was performed by the Taq DNA polymerase method (Saiki, R.K. et al.. Science 212:487-491 (1988)) using the TaqPaq kit (Biotech International, Bentley, WA) and the conditions recommended by the supplier with lOng of target DNA and lOpmol of ggtl 1 primers (New England BioLabs, Beverly, MA). RESULTS Isolation of Der f I cDNA clones Two clones expressing the major mite allergen Der fl were isolated from the P. farinae cPNA ggtl 1 library by their ability to hybridize with both of the Per p I cPNA probes (nucleotides 1-348 and 349-857). This approach was adopted because amino acid sequencing had shown high homology (80%) between these two allergens (Thomas, W.R., et al.. Advances in the Biosciences. 14:139-147 (1989)). Pigestion of the ggtl 1 fl clone PNA with EcoRI restriction enzyme to release the cPNA insert produced three Per fl cPNA EcoRI fragments: one approximately 800 bases long and a doublet approximately 150 bases long. The Per fl cPNA insert was also amplified from the phage PNA by the polymerase chain reaction (PCR) resulting in a PCR product of approximately 1.1-kb. Each Per fl cPNA fragment was cloned separately into the M13-derived sequencing vectors mpl8 and mpl9 and sequenced. PNA sequence analysis The nucleotide sequence of Denf I cPNA was determined using the sequencing strategy shown in Figure 9. The complete sequence was shown to be 1084 bases long and included a 335-base long 5' proximal end sequence, a coding region for the entire native Dfinf I protein of 223 amino acids with a derived molecular weight of 25,191 and an 80-base long 3* noncoding region (Fig. 10). The assignment of the threonine residue at position 1 as the NH2-terminal amino acid of Per f I was based on data obtained by NH2-terminal amino acid sequencing of the native protein and the predicted amino acid sequence of recombinant Per p I (Chua, K.Y. et al.. J. Exp. Med.. 167:175-182 (1988)). The predicted amino acid sequence of the Per fl cPNA in the NH2-terminal region matched completely with that determined at the protein level (Figures 10A and 10B). The complete mature protein coded by a single open reading frame terminating at the TGA stop codon at nucleotide position 42-44 is presumed to be the translation initiation site since the subsequent sequence codes for a typical signal peptide sequence. Amino Acid Sequence Analysis The amino acid sequence of Per f I predicted by nucleotide analysis is shown in Figures 10A and 10B. As shown in the composite alignment of the amino acid sequence of mature Per p I and Per fl (Figure 11), high homology was observed between the two proteins. Sequence homology analysis revealed that the Per fl protein showed 81 ) homology with the Per p I protein as predicted by previous conventional amino acid sequencing. In particular, the residues making up the active side of Per p I, based on those determined for papain, actinidin, cathepsin H, and cathepsin B, are also conserved in the Per fl protein. The residues are glutamine (residue 29), glycine, serine and cysteine (residues 33-35), histidine (residue 171) and asparagine, serine and tryptophan (residues 191-193) where the numbering refers to Per f I. The predicted mature Per fl amino acid sequence contains a potential N- glycosylation site (Asn-Thr-Ser) at position 53-55 which is also present as Asn-Gln- Ser at the equivalent position in Per p I. Analysis of the predicted amino acid sequence of the entire Per fl cPNA insert has shown that, as for other cysteine proteases (Figures 12A and 12B), the Per f I protein has pre- and proform intermediates. As previously mentioned, the methionine residue at position -98 is presumed to be the initiation methionine. This assumption is based on the fact that firstly, the 5' proximal end sequence from residues -98 to -81 is composed predominantly of hydrophobic amino acid residues (72%), which is the characteristic feature of signal peptides (Von Heijne, G., EMBO J.. 1:2315-2323 ( 1984)). Secondly, the lengths of the presumptive pre- (18 amino acid residues) and pro-peptides (80 residues) are similar to those for other cysteine proteases (Figures 12A and 12B). Most cysteine proteases examined have about 120 preproenzyme residues (of which an average of 19 residues form the signal peptide) with cathepsin B the smallest with 80 (Ishidoh, K. et al.. FEBS Letters. 226:32-37 (1987)). Per f l falls within this range with a total of 98 preproenzyme residues. S C i iRcyrτ; -T? c μ ∑rπτ « •_> z r~ \ By following the method for predicting signal-sequence cleavage sites outlined in Von Heijne, it is proposed that cleavage from the pre-Per fl sequence for proenzyme formation occurs at the signal peptidase cleavage site lying between Ala (-81) and Arg (-80) (Von Heijne, G., Eur. J. Biochem.. 133: 17- 21 (1988) and J. Mol. Biol.. 1£4:99-105 (1985)). Thus, the sequence from residues -98 to -81 codes for the leader peptide while the proenzyme moiety of Per fl begins at residue Arg (-80) and ends at residue Glu (-1). EXAMPLE 7 Isolation and Characterization of cPNA Coding for Per f II MATERIALS AND METHODS Amino acid sequence analysis Preparation of ggtl 1 D. farinae cDNA ligations D. farinae was purchased from Commonwealth Serum Laboratories, Parkville, Australia, and used to prepare mRNA (polyadenylated RNA) as described (Stewart, G.A. and W.R. Thomas, Int. Arch. Allergy Appl Immunol.. £1:384-389 (1987)). The mRNA was suspended at approximately 0.5mg/ml and 5mg used to prepare cDNA by the RNase H method (Gubler, U. and Hoffman, B.J., Gene. 21:263-269 (1983)) using a kit (Amersham International, Bucks). EcoRI linkers (Amersham, GGAATTCC) were attached according to the method described by Huynh et al.. Constructing and screening cDNA libraries in gtlO and gtl 1, In: Glover, DNA Cloning vol. A practical approach pp. 47-78 IRL Press, Oxford (1985)). The DNA was then digested with EcoRI and recovered from an agarose gel purification by electrophoresis into a DEAE membrane (Schleicher and Schuell, Dassel, FRG, NA-45) according to protocol 6.24 of Sambrook et al.. (Sambrook et al.. Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press (1989)), except 0.5M arginine base was used for elution. The cDNA was then ligated in ggtlO and ggtl 1 at an arms to insert ratio of 2:1. Some was packaged for plaque libraries and an aliquot retained for isolating sequences by polymerase chain reaction as described below. Isolation of Per f II cPNA bv Polymerase Chain Reaction To isolate Per f II cPNA, an oligonucleotide primer based on the N- terminal sequence of DSLP II was made because their amino acid residues are identical in these regions (Heymann, P.W. et al.. J. Allergy Clin. Immunol.. 51:1055-1087 (1989)). The primer GGATCCGATCAACTCGATGC-3' was used. The first GGATCC encodes a BamHI site and the following sequence GAT... encodes the first four residues of Dsrj2 II. For the other primer the ggtl 1 TTGACACCAGACCAACTGGTAATG-3' reverse primer flanking the EcoRI cloning site was used (New England Biolabs, Beverly, MA). The Per p II primer was designed to have approximately 50-60% G-C and to end on the first or second, rather than the third, base of a codon (Gould, S.J. et al.. Proc. Natl. Acad. Sci.. £6: 1934- 1938 (1989); Summer, R. and P. Tautz, Nucleic Acid Res.. 17:6749 (1989)). The PCR reactions were carried out in a final reaction volume of 25 ml containing 67mM Tris-HCL (pH8.8 at 25°C), 16.6mM (NH 4 ) S04, 40mM dNTPs, 5mM 2-mercaptoethanol, 6mM EPTA, 0.2mg/ml gelatin, 2mM MgCl2, lOpmoles of each primer and 2 units of Taq polymerase. Approximately O.OOlmg of target PNA was added and the contents of the tube were mixed and overlay ed with paraffin oil. The tubes were initially denatured at 95 °C for 6 minutes, then annealed at 55°C for 1 minute and extended at 72°C for 2 minutes. Thereafter for 38 cycles, denaturing was carried out for 30 seconds and annealing and extension as before. In the final (40th) cycle, the extension reacton was increased to 10 minutes to ensure that all amplified products were full length. The annealing temperature was deliberately set slightly lower than the Tm of the oligonucleotide primers (determined by the formula Tm=69.3 + 0.41 (G+C%)-650/oligo length) to allow for mismatches in the N-terminal primer. 5ml of the reaction was then checked for amplified bands on a 1% agarose gel. The remainder of the reaction mixture was extracted with chloroform to remove all of the paraffin oil and ethanol precipitated prior to purification of the amplified product on a low melting point agarose gel (Bio-Rad, Richmond, CA). Subcloning of PCR Product The ends of the purified PCR product were filled in a reaction containing 10 mM Tris HC1, 10 mM MgCl2, 50 mM NaCl, 0.025 mM dNTP and lml of Klenow enzyme in a final volume of 100ml. The reaction was carried out at 37°C for 15 minutes and heat inactivated at 70°C for 10 minutes. The mixture was Leder phenol extracted before ethanol precipitation. The resulting blunt ended PNA was ligated into M13mpll 8 digested with Sma I in a reaction containing 0.5M ATP, 1 X ligase buffer and 1 unit of T4 ligase at 15°C for 24 hrs and transformed into E. coli TGI made competent by the CaCl2 method. The transformed cells were plated out as a lawn on L + G plates and grown overnight at 37°C. Preparation of Single-stranded PNA Template for Sequencing Isolated white plaques were picked using an orange stick into 2.5 ml of an overnight culture of TGI cells diluted 1 in 100 in 2 X TY broth, and grown at 37°C for 6 hours. The cultures were pelleted and the supernatant removed to a fresh tube. To a lml aliquot of this supernatant 270ml of 20% polyethylene gly col, 2.5M NaCl was added and the tube was vortexed before allowing it to stand at room temperature (RT) for 15 minutes. This was then spun down again and all traces of the supernatant were removed from the tube. The pellet was then resuspended in 100ml of 1 X TE buffer. At least 2 phenol:TE extractions were done, followed by 1 Leder phenol extraction and a CHCP3 extraction. The PNA was precipitated in ethanol and resuspended in a final volume of 20ml of TE buffer. PNA Analysis PNA sequencing was performed with the dideoxynucleotide chain termination (Sanger, F. gLal, Proc. Natl. Acad. Sci.. 24:5463-5467 (1977)) using PNA produced from Ml 3 derived vectors mpl8 and mpl9 in E. coli TGI and T4 PNA polymerase (Sequenase version 2.0, USB Corp., Cleveland, Ohio; Restriction endonucleases were from Toyobo, (Osaka, Japan). All general procedures were by standard techniques (Sambrook, J. et al.. A Laboratory Manual, 2d Ed. Cold Spring Harbor Laboratory Press (1989)). The sequence analysis was performed using the Mac Vector Software (IBI, New Haven, CT). RESULTS P. farinae cPNA ligated in ggtl 1 was used to amplify a sequence using an oligonucleotide primer with homology to nucleotides coding for the 4 N- terminal residues of Per p II and a reverse primer for the ggtl 1 sequence flanking the coding site. Two major bands of about 500 bp and 300 bp were obtained when the product was gel electrophoresed. These were ligated into Ml 3 mpl8 and a number of clones containing the 500 bp fragment were analyzed by PNA sequencing. Three clones produced sequence data from the N-terminal primer end and one from the other orientation. Where the sequence data from the two directions overlapped, a complete match was found. One of the clones read from the N-terminal primer, contained a one-base deletion which shifted the reading frame. It was deduced to be a copying error, as the translated sequence from the other two clones matched the protein sequence for the first 20 amino acid residues of the allergen. The sequence of the clones showing consensus and producing a correct reading frame is shown in Figure 14, along with the inferred amino acid sequence. It coded for a 129 residue protein with no N-glycosylation site and a calculated molecular weight of 14,021 kP. No homology was found when compared to other proteins on the GenBank data base (61.0 release). It did, however, show 88% amino acid residue homology with Der p II shown in the alignment in Figures 16A, 16B, and 16C. Seven out of the 16 changes were conservative. The conserved residues also include all the cysteines present at positions 8, 21, 27, 73 and 119. There was also considerable nucleotide homology, although the restriction enzyme map generated from the sequence data for commonly used enzymes is different from Der p II (Figure 15). The hydrophobicity plots of the translated sequence of Der_f II and Der p II shown in Figures 17A and 17B are almost identical. EXAMPLE 8 Determination of Nucleotide Sequence Polymorphisms in the Der p I. Der p II and Der f II Allergens It was expected that there were sequence polymorphisms in the nucleic acid sequence coding for Der p I, Der p II, Der fl and Der f II. due to natural allelic variation among individual mites. Several nucleotide and resulting amino acid sequence polymorphisms were discovered during the sequencing of different Der p I, Der p II and Der f II clones. The amino acid sequence polymorphisms are shown in Figures 18, 19 and 20. The original Der p I ggtl 1 cDNA library was reprobed with cDNA obtained from the ggtl 1 pl(13T) clone to identify new clones. Similarly, the ggtl 1 cDNA library of Der p II was reprobed with cDNA obtained from the ggtl 1 pII(Cl) clone to identify additional Der p II clones. These clones were isolated, sequenced and found to contain nucleotide and resulting amino acid sequence polymorphisms (see Fig. 18 and 19). Four Der p I clones, (b), (c), (d) and (e) were sequenced, as shown in Fig. 18. Clone Der p 1(d) was found to contain the following polymorphisms relative to the clone Der p 1(a) sequence: (1) the codon for amino acid residue 136 was ACC rather than AGC, which results in a predicted amino acid substitution of Thr for Ser; (2) the codon for amino acid residue 149 had a silent mutation, GCT rather than GCA; and (3) the codon for amino acid residue 215 was CAA rather than GAA; which results in a predicted amino acid substitution of Gin for Glu. The Der II clones, Per p 11(1) and Per p 11(2) were sequenced as shown in Figure 19. Clone Per p 11(2) was found to have the codon TCA, rather than ACA at amino acid residue 47, which results in a predicted amino acid substitution of Ser for Thr. This clone also was found to have the codon AAT at amino acid residue 113 rather than GAT, which results in a predicted amino acid substitution of Asn for Asp. The codon for amino acid 127 of this clone was found to be CTC rather than ATC. This change in codon 127 results in a predicted amino acid substitution of Leu for He. Additional Per f II cPNA clones containing nucleic acid and resulting amino acid sequence polymoφhisms were obtained from PCR reactions using cPNA prepared with RNA isolated from P. farinae mites (Commonwealth Serum Laboratories, Parksville, Australia). cPNA was prepared and ligated in ggtlO as previously described (Trudinger fit aL (1991) Clin. Exp. Allergy 21:33- 37). The clones described below were isolated following PCR of the ggt 10 library using a 5' primer, which had the sequence 5 * -GGATCCGATCAAGTCGATGT-3'. The nucleotides 5'-GGATCC-3' of the 5' primer correspond to a Bam HI endonuclease site added for cloning piuposes. The remaining nucleotides of the 5' primer, 5'-GATCAAGTCGATGT-3' correspond to the first 4 amino acids of Per p II (Chua et al. (1990) Int. Arch. Allergy Clin. Immunol. 91 :1 18-123) as described in Trudinger et al. (T1991) Clin. Exp. Allergy 21:33-371 The 3' primer, which has the sequence S'-TTGACACCAGACCAACTGGTAATG-S', corresponds to a sequence of the ggtlO cloning vector (Trudinger fit aL supra). PCR was performed as described (Trudinger fit aL supra) and four Per f II clones, MT3, MT5, MT16 and MT18, were sequenced, as shown in Figure 20. Three clones were sequenced that had potential polymorphisms relative to the published Dfiii " II sequence (Trudinger fit aL supra). The codon for amino acid 52 of clone MT18 was ATT rather than the published ACT (Trudinger el aL supra). This change in codon 52 of clone MT18 would result in a predicted amino acid change from Thr to He. Clone MT5 contained three changes from the published sequence (Trudinger fit aL supra : (1) the codon for amino acid 11 was AGC rather than the published AAC (Trudinger fit aL supra), which results in a predicted amino acid substitution of Ser for Asn; (2) the codon for amino acid 52 was ATT, rather than the published ACT (Trudinger fit aL supra), which results in a predicted amino acid substitution of He for Thr; and (3) the codon for amino acid 88 was ATC rather than the published GCC (Trudinger fit aL supra), which results in a predicted amino acid substitution of He for Ala. Clone MT16 had a silent mutation in the codon for amino acid 68 (ATC versus the published ATT (Trudinger et aL supra) that did not change the predicted amino acid at this residue. The following substitutes were also observed by Yuuki et al. (Jpn.J.Allergol. 6:557-561, 1990); He at residue 52, He at residue 54 and He at residue 88. Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. REFERENCES 1. Ford, A.W., Rawle, F.C., Lind, P., Spieksma, F.T.M., Lowenstein, H., Platts-Mills, T.A.E. (1985). Standardization of Permatophagoides pteronyssinus. Assessment of potency and allergen content in the coded extracts. In Arch. Allergy Appl. Immunol. 26:58-67. 2. Lind, P., Lowenstein, H. (1983). Identification of allergens in Permatophagoides pteronyssinus mite body extract by crossed radioimmunelectrophoresis with two different rabbit antibody pools. Scand. Immunol. 12:263-273. 3. Krilis, S., Baldo, B.A., Basten, A. (1984). Antigens and allergens from the common house dust mite Permatophagoides pteronyssinus Part II. Identification of the major IgE binding antigens by crossed radioimmuno- electrophoresis. J. Allergy Clin. Immunol. 74:142-146. 4. Tovey, E.R., Chapman, M.P., Platts-Mills, T.A E. (1981). Mite faeces are a major source of house dust allergens. Nature 289_:592- 593. 5. Gubler, U., Hoffman, B.J. (1983). A simple and very efficient method for generating cPNA libraries. Gene 21:263-269. 6. Huynh, T.V., Young, R.A., Pavis, R.W. Constructing and screening cPNA libraries in glO and ggtl 1. p48-78 in PNA Cloning Col. 1, A practical approach. Ed. P.M. Glover, IRL press. 7. Stewart, G.A., Thomas, W.R. (1987). In vitro translation of messenger RNA from the house mite Permatophagoides pteronyssinus. Int. Arch. Allergy Appl. Immunol. 83:384-389. 8. Thomas, W.R., Rossi, A.A. (1986). Molecular cloning of PNA coding for outer membrane proteins of Haemophilus influenzae type b. Infection and Immunity 52:812-817. 9. Simpson, R.J., Smith, J.A., Mortiz. R.L., O'Hare, M.J., Rudland. P.S., Morrison, J.R., Lloyd, C.J., Grego, B., Burgess, A.W. and Nice, E.L. (1985). Rat Epidermal Growth Factor: Complete amino acid sequence. Eur. . Biochem. 153:629-637. 10. Maniatis, T., Fritsch, E.F., Sambrook, J. (1982). Molecular cloning. A Laboratory Manual, Cold Spring Harbor Laboratory. 11. Sanger, F., Nicklen, S., Coulson, A.R. (1977). PNA sequencing with chain- terminating inhibitors. Proc. Natl. Acad. ≤ci 24:5463-5467. 12. Heyman, P.W., Chapman, M.P., Platts-Mills, T.A.E. (1986). Antigen Per fl from the house dust mite Permatophagoides farinae: Structural comparison with Per p I from Permatophagoides pteronyssinus and epitope specificity of murine IgG and human IgE antibodies. J. Immunol. 137:2841-2847. 13. Voorhorst, R., Spieksma-Boezeman, M.I. A., and Spieksma, F. Th.M. (1964). Is a mite fPermatophagoides sp) the producer of the house dust allergen. Allerg. Asthma. J_0_:329. 14. Voorhorst, R., Spieksma, F.Th.M., Varekamp, H., Leupen, M.J. and Lyklema, A.W., (1967). The house dust mite (Permatophagoides pteronyssinus) and the allergens it produces. Identity with the house dust allergen. J. Allergy. 39:325. 15. Stewart, G.A. and Thomas, W.R. (1987). In vitro translation of messenger RNA from the house dust mite Permatophagoides pteronyssinus. InL ήieh- Allergy AppL Immunol, £1:384. 16. Messing, J. (1983). New M13 vectors for cloning. Methods 101 :20. 17. Stewart, G.A., Simpson, R.J., Thomas, W.R. and Turner, K.J. ( 1986). The physiochemical characterization of a major protein allergen from the house dust mite, EP. Asian Pac. Allergy Imnunol. 1:71. 18. Kozak, M. (1984). Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic. Acids Res. 12:857. 19. San Segundo, B., Chain, S.J. and Steiner, m (1985). Identification of cPNA clones encoding a precursor of rat liver cathepsin B. Proc. Natl. Acad. Sci. USA. £2:2320. 20. Portnoy, P.A., Erickson, A.H., Kochan, J., Ravetch, J.V. and Unkeless, J.C. (1986). Cloning and characterization of a mouse cysteine proteinase. J. Biol. Chem. 261 :14697. 21. Williams, J.G., North, M.J. and Mahbubani, H. (1985). A developmentally regulated cysteine proteinase in Pictyostelium discQideum. EMBO (EUL MΩL Biol Organ,) L 4:999. 22. Hopp, T.P. (1986). Protein surface analysis. Method for identifying antigenic determinants and other interaction sites. L Immunol. Methods. 88:1. 23. Von Heijne, G. (1984). Analysis of the distribution of charged residues in the N-terminal region of signal sequences: implications of protein export in prokaryotic and eukaryotic cells. EMBO (Eur. Mol. _EioL Qrga ) Ll:2315. 24. Ullrich, A., Shine, J., Chirgwin, J., Pictet, R., Tischer, E., Rutter, W.J. and Goodman, H.W. (1977). Rat insulin genes: Construction of plasmids containing th coding sequences. Science (Wash. PC) 126:1313. 25. Carne, T. and Scheele, G. (1985). Cell Biology of the Secretory Process. M.Cantin, editor. S. Karger AG, Basel. 73. 26. Smith, P. and Johnson (1988), Gene (in press). 27. Thomas, W.R. and Rossi, A.A. (1986). Molecular cloning of PNA coding for outer membrane proteins of Haemophilus influenzae Type b. Infection and Immunity 52:812-817. 28. Thomas, W.R., Stewart, G.A., Simpson, R.J., Chua, K.Y., Plozza, T.M., Pilworth, Pr. U., Nisbet, A. and Turner, K.J. (1987). Cloning and expression of PNA coding for the major house dust mite allergen Per p I in Escherichia coli. Int. Arch. Allergy Appl. Immunol. £1: 127-129. 29. Stewart, G.A.. and Holt, P.G. (1987). Immunogenicity and tolerogenicity of a major house dust mite allergen Dfi p I. Int. Arch. Allergy Appl. Immunol. 83:44-51. 31. Chapman, M.P., Heymann, P.W. and Platts-Mills, T.A.E. (1987). Mite allergens 1. Epitope mapping of major dust mite (Permatophagoides) allergens using monoclonal antibodies. Mite Allergy - A World Wide Problem. Ed. A.L. deWeck and A. Todt. The UCB Institute of Allergy. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) (i) APPLICANT: (A) NAME: IMMULOGIC PHARMACEUTICAL CORPORATION (B) STREET: 610 LINCOLN STREET (C) CITY: WALTHAM (D) STATE: MASSACHUSETTS (E) COUNTRY: USA (F) POSTAL CODE (ZIP) : 02154 (G) TELEPHONE: (617) 466-6000 (H) TELEFAX: (617) 466-6010 (ii) TITLE OF INVENTION: CLONING AND SEQUENCING OF ALLERGENS FROM DERMATOPHAGOIDES (HOUSE DUST MITES) (iii) NUMBER OF SEQUENCES: 13 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: LAHIVE & COCKFIELD (B) STREET: 60 STATE STREET, SUITE 510 (C) CITY: BOSTON (D) STATE: MA (E) COUNTRY: USA (F) ZIP: 02109 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: ASCII TEXT (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 07/945,288 (B) FILING DATE: 10 SEPTEMBER 1992 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (617) 227-7400 (B) TELEFAX: (617) 227-5941 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 834 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..738 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: AAA AAC CGA TTT TTG ATG AGT GCA GAA GCT TTT GAA CAC CTC AAA ACT 48 Lys Asn Arg Phe Leu Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr -23 -20 -15 -10 CAA TTC GAT TTG AAT GCT GAA ACT AAC GCC TGC AGT ATC AAT GGA AAT 96 Gin Phe Asp Leu Asn Ala Glu Thr Asn Ala Cys Ser lie Asn Gly Asn -5 -1 1 5 GCT CCA GCT GAA ATC GAT TTG CGA CAA ATG CGA ACT GTC ACT CCC ATT 144 Ala Pro Ala Glu lie Asp Leu Arg Gin Met Arg Thr Val Thr Pro lie 10 15 20 25 CGT ATG CAA GGA GGC TGT GGT TCA TGT TGG GCT TTC TCT GGT GTT GCC 192 Arg Met Gin Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val Ala 30 35 40 GCA ACT GAA TCA GCT TAT TTG GCT CAC CGT AAT CAA TCA TTG GAT CTT 240 Ala Thr Glu Ser Ala Tyr Leu Ala His Arg Asn Gin Ser Leu Asp Leu 45 50 55 GCT GAA CAA GAA TTA GTC GAT TGT GCT TCC CAA CAC GGT TGT CAT GGT 288 Ala Glu Gin Glu Leu Val Asp Cys Ala Ser Gin His Gly Cys His Gly 60 65 70 GAT ACC ATT CCA CGT GGT ATT GAA TAC ATC CAA CAT AAT GGT GTC GTC 336 Asp Thr lie Pro Arg Gly He Glu Tyr He Gin His Asn Gly Val Val 75 80 85 CAA GAA AGC TAC TAT CGA TAC GTT GCA CGA GAA CAA TCA TGC CGA CGA 384 Gin Glu Ser Tyr Tyr Arg Tyr Val Ala Arg Glu Gin Ser Cys Arg Arg 90 95 100 105 CCA AAT GCA CAA CGT TTC GGT ATC TCA AAC TAT TGC CAA ATT TAC CCA 432 Pro Asn Ala Gin Arg Phe Gly He Ser Asn Tyr Cys Gin He Tyr Pro 110 115 120 CCA AAT GCA AAC AAA ATT CGT GAA GCT TTG GCT CAA ACC CAC AGC GCT 480 Pro Asn Ala Asn Lys He Arg Glu Ala Leu Ala Gin Thr His Ser Ala 125 130 135 ATT GCC GTC ATT ATT GGC ATC AAA GAT TTA GAC GCA TTC CGT CAT TAT 528 He Ala Val He He Gly He Lys Asp Leu Asp Ala Phe Arg His Tyr 140 145 150 GAT GGC CGA ACA ATC ATT CAA CGC GAT AAT GGT TAC CAA CCA AAC TAT 576 Asp Gly Arg Thr He He Gin Arg Asp Asn Gly Tyr Gin Pro Asn Tyr 155 160 165 CAC GCT GTC AAC ATT GTT GGT TAC AGT AAC GCA CAA GGT GTC GAT TAT 624 His Ala Val Asn He Val Gly Tyr Ser Asn Ala Gin Gly Val Asp Tyr 170 175 180 185 TGG ATC GTA CGA AAC AGT TGG GAT ACC AAT TGG GGT GAT AAT GGT TAC 672 Trp He Val Arg Asn Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr 190 195 200 GGT TAT TTT GCT GCC AAC ATC GAT TTG ATG ATG ATT GAA GAA TAT CCA 720 Gly Tyr Phe Ala Ala Asn He Asp Leu Met Met He Glu Glu Tyr Pro 205 210 215 TAT GTT GTC ATT CTC TAAACAAAAA GACAATTTCT TATATGATTG TCACTAATTT 775 Tyr Val Val He Leu 220 ATTTAAAATC AAAATTTTTT AGAAAATGAA TAAATTCATT CACAAAAATT AAAAAAAAA 834 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 245 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 : Lys Asn Arg Phe Leu Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr -23 -20 -15 -10 Gin Phe Asp Leu Asn Ala Glu Thr Asn Ala Cys Ser He Asn Gly Asn -5 -1 1 5 Ala Pro Ala Glu He Asp Leu Arg Gin Met Arg Thr Val Thr Pro He 10 15 20 25 Arg Met Gin Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val Ala 30 35 40 Ala Thr Glu Ser Ala Tyr Leu Ala His Arg Asn Gin Ser Leu Asp Leu 45 50 55 Ala Glu Gin Glu Leu Val Asp Cys Ala Ser Gin His Gly Cys His Gly 60 65 70 Asp Thr He Pro Arg Gly He Glu Tyr He Gin His Asn Gly Val Val 75 80 85 Gin Glu Ser Tyr Tyr Arg Tyr Val Ala Arg Glu Gin Ser Cys Arg Arg 90 95 100 105 Pro Asn Ala Gin Arg Phe Gly He Ser Asn Tyr Cys Gin He Tyr Pro 110 115 120 Pro Asn Ala Asn Lys He Arg Glu Ala Leu Ala Gin Thr His Ser Ala 125 130 135 He Ala Val He He Gly He Lys Asp Leu Asp Ala Phe Arg His Tyr 140 145 150 Asp Gly Arg Thr He He Gin Arg Asp Asn Gly Tyr Gin Pro Asn Tyr 155 160 165 His Ala Val Asn He Val Gly Tyr Ser Asn Ala Gin Gly Val Asp Tyr 170 175 180 185 Trp He Val Arg Asn Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr 190 195 200 Gly Tyr Phe Ala Ala Asn He Asp Leu Met Met He Glu Glu Tyr Pro 205 210 215 Tyr Val Val He Leu 220 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 588 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 69..509 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 : CACAAATTCT TCTTTCTTCC TTACTACTGA TCATTAATCT GAAAACAAAA CCAAACAAAC 60 CATTCAAA ATG ATG TAC AAA ATT TTG TGT CTT TCA TTG TTG GTC GCA GCC 110 Met Tyr Lys He Leu Cys Leu Ser Leu Leu Val Ala Ala -16 -15 -10 -5 GTT GCT CGT GAT CAA GTC GAT GTC AAA GAT TGT GCC AAT CAT GAA ATC 158 Val Ala Arg Asp Gin Val Asp Val Lys Asp Cys Ala Asn His Glu He -1 1 5 10 AAA AAA GTT TTG GTA CCA GGA TGC CAT GGT TCA GAA CCA TGT ATC ATT 206 Lys Lys Val Leu Val Pro- Gly Cys His Gly Ser Glu Pro Cys He He 15 20 25 CAT CGT GGT AAA CCA TTC CAA TTG GAA GCC GTT -TTC GAA GCC AAC CAA 254 His Arg Gly Lys Pro Phe Gin Leu Glu Ala Val Phe Glu Ala Asn Gin 30 35 40 45 AAC ACA AAA ACG GCT AAA ATT GAA ATC AAA GCC TCA ATC GAT GGT TTA 302 Asn Thr Lys Thr Ala Lys He Glu He Lys Ala Ser He Asp Gly Leu 50 55 60 GAA GTT GAT GTT CCC GGT ATC GAT CCA AAT GCA TGC CAT TAC ATG AAA 350 Glu Val Asp Val Pro Gly He Asp Pro Asn Ala Cys His Tyr Met Lys 65 70 75 TGC CCA TTG GTT AAA GGA CAA CAA TAT GAT ATT AAA TAT ACA TGG AAT 398 Cys Pro Leu Val Lys Gly Gin Gin Tyr Asp He Lys Tyr Thr Trp Asn 80 85 90 GTT CCG AAA ATT GCA CCA AAA TCT GAA AAT GTT GTC GTC ACT GTT AAA 446 Val Pro Lys He Ala Pro Lys Ser Glu Asn Val Val Val Thr Val Lys 95 100 105 GTT ATG GGT GAT GAT GGT GTT TTG GCC TGT GCT ATT GCT ACT CAT GCT 494 Val Met Gly Asp Asp Gly Val Leu Ala Cys Ala He Ala Thr His Ala 110 115 120 125 AAA ATC CGC GAT TAAATAAACA AAATTTATTG ATTTTGTAAT CACAAATGAT 546 Lys He Arg Asp TGATTTTCTT TCCAAAAAAA AAATAAATAA AATTTTGGGA AT 588 (2) INFORMATION FOR SEQ ID NO:4 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 146 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Met Tyr Lys He Leu Cys Leu Ser Leu Leu Val Ala Ala Val Ala -16 -15 -10 -5 Arg Asp Gin Val Asp Val Lys Asp Cys Ala Asn His Glu He Lys Lys -1 1 5 10 15 Val Leu Val Pro Gly Cys His Gly Ser Glu Pro Cys He He His Arg 20 25 30 Gly Lys Pro Phe Gin Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr 35 40 45 Lys Thr Ala Lys He Glu He Lys Ala Ser He Asp Gly Leu Glu Val 50 55 60 Asp Val Pro Gly He Asp Pro Asn Ala Cys His Tyr Met Lys Cys Pro 65 70 75 Leu Val Lys Gly Gin Gin Tyr Asp He Lys Tyr Thr Trp Asn Val Pro 80 85 90 95 Lys He Ala Pro Lys Ser Glu Asn Val Val Val Thr Val Lys Val Met 100 105 110 Gly Asp Asp Gly Val Leu Ala Cys Ala He Ala Thr His Ala Lys He 115 120 125 Arg Asp (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1072 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA ( ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 36..1001 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: CGTTTTCTTC CATCAAAATT AAAAATTCAT CAAAA ATG AAA TTC GTT TTG GCC 53 Met Lys Phe Val Leu Ala -98 -95 ATT GCC TCT TTG TTG GTA TTG AGC ACT GTT TAT GCT CGT CCA GCT TCA 101 He Ala Ser Leu Leu Val Leu Ser Thr Val Tyr Ala Arg Pro Ala Ser -90 -85 -80 ATC AAA ACT TTT GAA GAA TTC AAA AAA GCC TTC AAC AAA AAC TAT GCC 149 He Lys Thr Phe Glu Glu Phe Lys Lys Ala Phe Asn Lys Asn Tyr Ala -75 -70 -65 ACC GTT GAA GAG GAA GAA GTT GCC CGT AAA AAC TTT TTG GAA TCA TTG 197 Thr Val Glu Glu Glu Glu Val Ala Arg Lys Asn Phe Leu Glu Ser Leu -60 -55 -50 -45 AAA TAT GTT GAA GCT AAC AAA GGT GCC ATC AAC CAT TTG TCC GAT TTG 245 Lys Tyr Val Glu Ala Asn Lys Gly Ala He Asn His Leu Ser Asp Leu -40 -35 -30 TCA TTG GAT GAA TTC AAA AAC CGT TAT TTG ATG AGT GCT GAA GCT TTT 293 Ser Leu Asp Glu Phe Lys Asn Arg Tyr Leu Met Ser Ala Glu Ala Phe -25 -20 -15 GAA CAA CTC AAA ACT CAA TTC GAT TTG AAT GCC GAA ACA AGC GCT TGC 341 Glu Gin Leu Lys Thr Gin Phe Asp Leu Asn Ala Glu Thr Ser Ala Cys -10 -5 -1 1 CGT ATC AAT TCG GTT AAC GTT CCA TCG GAA TTG GAT TTA CGA TCA CTG 389 Arg He Asn Ser Val Asn Val Pro Ser Glu Leu Asp Leu Arg Ser Leu 5 10 15 20 CGA ACT GTC ACT CCA ATC CGT ATG CAA GGA GGC TGT GGT TCA TGT TGG 437 Arg Thr Val Thr Pro He Arg Met Gin Gly Gly Cys Gly Ser Cys Trp 25 30 35 GCT TTC TCT GGT GTT GCC GCA ACT GAA TCA GCT TAT TTG GCC TAC CGT 485 Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu Ala Tyr Arg 40 45 50 AAC ACG TCT TTG GAT CTT TCT GAA CAG GAA CTC GTC GAT TGC GCA TCT 533 Asn Thr Ser Leu Asp Leu Ser Glu Gin Glu Leu Val Asp Cys Ala Ser 55 60 65 CAA CAC GGA TGT CAC GGC GAT ACA ATA CCA AGA GGC ATC GAA TAC ATC 581 Gin His Gly Cys His Gly Asp Thr He Pro Arg Gly He Glu Tyr He 70 75 80 CAA CAA AAT GGT GTC GTT GAA GAA AGA AGC TAT CCA TAC GTT GCA CGA 629 Gin Gin Asn Gly Val Val Glu Glu Arg Ser Tyr Pro Tyr Val Ala Arg 85 90 95 100 GAA CAA CGA TGC CGA CGA CCA AAT TCG CAA CAT TAC GGT ATC TCA AAC 677 Glu Gin Arg Cys Arg Arg Pro Asn Ser Gin His Tyr Gly He Ser Asn 105 110 115 TAC TGC CAA ATT TAT CCA CCA GAT GTG AAA CAA ATC CGT GAA GCT TTG 725 Tyr Cys Gin He Tyr Pro Pro Asp Val Lys Gin He Arg Glu Ala Leu 120 125 130 ACT CAA ACA CAC ACA GCT ATT GCC GTC ATT ATT GGC ATC AAA GAT TTG 773 Thr Gin Thr His Thr Ala He Ala Val He He Gly He Lys Asp Leu 135 140 145 AGA GCT TTC CAA CAT TAT GAT GGA CGA ACA ATC ATT CAA CAT GAC AAT 821 Arg Ala Phe Gin His Tyr Asp Gly Arg Thr He He Gin His Asp Asn 150 155 160 GGT TAT CAA CCA AAC TAT CAT GCC GTC AAC ATT GTC GGT TAC GGA AGT 869 Gly Tyr Gin Pro Asn Tyr His Ala Val Asn He Val Gly Tyr Gly Ser 165 170 175 180 ACA CAA GGC GAC GAT TAT TGG ATC GTA CGA AAC AGT TGG GAT ACT ACC 917 Thr Gin Gly Asp Asp Tyr Trp He Val Arg Asn Ser Trp Asp Thr Thr 185 190 195 TGG GGA GAT AGC GGA TAC GGA TAT TTC CAA GCC GGA AAC AAC CTC ATG 965 Trp Gly Asp Ser Gly Tyr Gly Tyr Phe Gin Ala Gly Asn Asn Leu Met 200 205 210 ATG ATC GAA CAA TAT CCA TAT GTT GTA ATC ATG TGAACATTTG AAATTGAATA 1018 Met He Glu Gin Tyr Pro Tyr Val Val He Met 215 220 TATTTATTTG TTTTCAAAAT AAAAACAACT ACTCTTGCGA GTATTTTTTA CTCG 1072 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 321 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6 : Met Lys Phe Val Leu Ala He Ala Ser Leu Leu Val Leu Ser Thr Val -98 -95 -90 -85 Tyr Ala Arg Pro Ala Ser He Lys Thr Phe Glu Glu Phe Lys Lys Ala -80 -75 -70 Phe Asn Lys Asn Tyr Ala Thr Val Glu Glu Glu Glu Val Ala Arg Lys -65 -60 -55 Asn Phe Leu Glu Ser Leu Lys Tyr Val Glu Ala Asn Lys Gly Ala He -50 -45 -40 -35 Asn His Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Tyr Leu -30 -25 -20 Met Ser Ala Glu Ala Phe Glu Gin Leu Lys Thr Gin Phe Asp Leu Asn -15 -10 -5 Ala Glu Thr Ser Ala Cys Arg He Asn Ser Val Asn Val Pro Ser Glu -1 1 5 10 Leu Asp Leu Arg Ser Leu Arg Thr Val Thr Pro He Arg Met Gin Gly 15 20 25 30 Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser 35 40 45 Ala Tyr Leu Ala Tyr Arg Asn Thr Ser Leu Asp Leu Ser Glu Gin Glu 50 55 60 Leu Val Asp Cys Ala Ser Gin His Gly Cys His Gly Asp Thr He Pro 65 70 75 Arg Gly He Glu Tyr He Gin Gin Asn Gly Val Val Glu Glu Arg Ser 80 85 90 Tyr Pro Tyr Val Ala Arg Glu Gin Arg Cys Arg Arg Pro Asn Ser Gin 95 100 105 110 His Tyr Gly He Ser Asn Tyr Cys Gin He Tyr Pro Pro Asp Val Lys 115 120 125 Gin He Arg Glu Ala Leu Thr Gin Thr His Thr Ala He Ala Val He 130 135 140 He Gly He Lys Asp Leu Arg Ala Phe Gin His Tyr Asp Gly Arg Thr 145 150 155 He He Gin His Asp Asn Gly Tyr Gin Pro Asn Tyr His Ala Val Asn 160 165 170 He Val Gly Tyr Gly Ser Thr Gin Gly Asp Asp Tyr Trp He Val Arg 175 180 185 190 Asn Ser Trp Asp Thr Thr Trp Gly Asp Ser Gly Tyr Gly Tyr Phe Gin 195 200 205 Ala Gly Asn Asn Leu Met Met He Glu Gin Tyr Pro Tyr Val Val He 210 215 220 Met (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 491 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA ( ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 1..390 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: GAT CAA GTC GAT GTT AAA GAT TGT GCC AAC AAT GAA ATC AAA AAA GTA 48 Asp Gin Val Asp Val Lys Asp Cys Ala Asn Asn Glu He Lys Lys Val 1 5 10 15 ATG GTC GAT GGT TGC CAT GGT TCT GAT CCA TGC ATA ATC CAT CGT GGT 96 Met Val Asp Gly Cys His Gly Ser Asp Pro Cys He He His Arg Gly 20 25 30 AAA CCA TTC ACT TTG GAA GCC TTA TTC GAT GCC AAC CAA AAC ACT AAA 144 Lys Pro Phe Thr Leu Glu Ala Leu Phe Asp Ala Asn Gin Asn Thr Lys 35 40 45 ACC GCT AAA ACT GAA ATC AAA GCC AGC CTC GAT GGT CTT GAA ATT GAT 192 Thr Ala Lys Thr Glu He Lys Ala Ser Leu Asp Gly Leu Glu He Asp 50 55 60 GTT CCC GGT ATT GAT ACC AAT GCT TGC CAT TTT ATG AAA TGT CCA TTG 240 Val Pro Gly He Asp Thr Asn Ala Cys His Phe Met Lys Cys Pro Leu 65 70 75 80 GTT AAA GGT CAA CAA TAT GAT GCC AAA TAT ACA TGG AAT GTG CCC AAA 288 Val Lys Gly Gin Gin Tyr Asp Ala Lys Tyr Thr Trp Asn Val Pro Lys 85 90 95 ATT GCA CCA AAA TCT GAA AAC GTT GTC GTT ACA GTC AAA CTT GTT GGT 336 He Ala Pro Lys Ser Glu Asn Val Val Val Thr Val Lys Leu Val Gly 100 105 110 GAT AAT GGT GTT TTG GCT TGC GCT ATT GCT ACC CAC GCT AAA ATC CGT 384 Asp Asn Gly Val Leu Ala Cys Ala He Ala Thr His Ala Lys He Arg 115 120 125 GAT TAAAAAAAAA AAATAAATAT GAAAATTTTC ACCAACATCG AACAAAATTC 437 Asp 130 AATAACCAAA ATTTGAATCA AAAACGGAAT TCCAAGCTGA GCGCCGGTCG CTAC 491 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 129 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8 : Asp Gin Val Asp Val Lys Asp Cys Ala Asn Asn Glu He Lys Lys Val 1 5 10 15 Met Val Asp Gly Cys His Gly Ser Asp Pro Cys He He His Arg Gly 20 25 30 Lys Pro Phe Thr Leu Glu Ala Leu Phe Asp Ala Asn Gin Asn Thr Lys 35 40 45 Thr Ala Lys Thr Glu He Lys Ala Ser Leu Asp Gly Leu Glu He Asp 50 55 60 Val Pro Gly He Asp Thr Asn Ala Cys His Phe Met Lys Cys Pro Leu 65 70 75 80 Val Lys Gly Gin Gin Tyr Asp Ala Lys Tyr Thr Trp Asn Val Pro Lys 85 90 95 He Ala Pro Lys Ser Glu Asn Val Val Val Thr Val Lys Leu Val Gly 100 105 110 Asp Asn Gly Val Leu Ala Cys Ala He Ala Thr His Ala Lys He Arg 115 120 125 Asp (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1172 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..738 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9;- GAATTCCTTT TTTTTTCTTT CTCTCTCTAA AATCTAAAAT CCATCCAAC ATG AAA ATT 58 Met Lys He -98 GTT TTG GCC ATC GCC TCA TTG TTG GCA TTG AGC GCT GTT TAT GCT CGT 106 Thr Leu Ala He Ala Ser Leu Leu Ala Leu Ser Ala Val Tyr Ala Arg -95 -90 -85 -80 CCA TCA TCG ATC AAA ACT TTT GAA GAA TAC AAA AAA GCC TTC AAC AAA 154 Pro Ser Ser He Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn Lys -75 -70 -65 AGT TAT GCT ACC TTC GAA GAT CAA GAA GCT GCC CGT AAA AAC TTT TTG 202 Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe Leu -60 -55 -50 GAA TCA GTA AAA TAT GTT CAA TCA AAT GGA GGT GCC ATC AAC CAT TTG 250 Glu Ser Val Lys Tyr Val Gin Ser Asn Gly Gly Ala He Asn His Leu -45 -40 -35 TCC GAT TTG TCG TTG GAT GAA TTC AAA AAC CGA TTT TTG ATG AGT GCA 298 Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser Ala -30 -25 -20 GAA GCT TTT GAA CAC CTC AAA ACT CAA TTC GAT TTG AAT GCT GAA ACT 346 Glu Ala Phe Glu His Leu Lys Thr Gin Phe Asp Leu Asn Ala Glu Thr -15 -10 -5 -1 1 AAC GCC TGC AGT ATC AAT GGA AAT GCT CCA GCT GAA ATC GAT TTG CGA 394 Asn Ala Cys Ser He Asn Gly Asn Ala Pro Ala Glu He Asp Leu Arg 5 10 15 CAA ATG CGA ACT GTC ACT CCC ATT CGT ATG CAA GGA GGC TGT GGT TCA 442 Gin Met Arg Thr Val Thr Pro He Arg Met Gin Gly Gly Cys Gly Ser 20 25 30 TGT TGG GCT TTC TCT GGT GTT GCC GCA ACT GAA TCA GCT TAT TTG GCT 490 Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu Ala 35 40 45 CAC CGT AAT CAA TCA TTG GAT CTT GCT GAA CAA GAA TTA GTC GAT TGT 538 His Arg Asn Gin Ser Leu Asp Leu Ala Glu Gin Glu Leu Val Asp Cys 50 55 60 65 GCT TCC CAA CAC GGT TGT CAT GGT GAT ACC ATT CCA CGT GGT ATT GAA 586 Ala Ser Gin His Gly Cys His Gly Asp Thr He Pro Arg Gly He Glu 70 75 80 TAC ATC CAA CAT AAT GGT GTC GTC CAA GAA AGC TAC TAT CGA TAC GTT 634 Tyr He Gin His Asn Gly Val Val Gin Glu Ser Tyr Tyr Arg Tyr Val 85 90 95 GCA CGA GAA CAA TCA TGC CGA CGA CCA AAT GCA CAA CGT TTC GGT ATC 682 Ala Arg Glu Gin Ser Cys Arg Arg Pro Asn Ala Gin Arg Phe Gly He 100 105 110 TCA AAC TAT TGC CAA ATT TAC CCA CCA AAT GCA AAC AAA ATT CGT GAA 730 Ser Asn Tyr Cys Gin He Tyr Pro Pro Asn Ala Asn Lys He Arg Glu 115 120 125 GCT TTG GCT CAA ACC CAC AGC GCT ATT GCC GTC ATT ATT GGC ATC AAA 778 Ala Leu Ala Gin Thr His Ser Ala He Ala Val He He Gly He Lys 130 135 140 145 GAT TTA GAC GCA TTC CGT CAT TAT GAT GGC CGA ACA ATC ATT CAA CGC 826 Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr He He Gin Arg 150 155 160 GAT AAT GGT TAC CAA CCA AAC TAT CAC GCT GTC AAC ATT GTT GGT TAC 874 Asp Asn Gly Tyr Gin Pro Asn Tyr His Ala Val Asn He Val Gly Tyr 165 170 175 AGT AAC GCA CAA GGT GTC GAT TAT TGG ATC GTA CGA AAC AGT TGG GAT 922 Ser Asn Ala Gin Gly Val Asp Tyr Trp He Val Arg Asn Ser Trp Asp 180 185 190 ACC AAT TGG GGT GAT AAT GGT TAC GGT TAT TTT GCT GCC AAC ATC GAT 970 Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn He Asp 195 200 205 TTG ATG ATG ATT GAA GAA TAT CCA TAT GTT GTC ATT CTC TAAACAAAAA 1019 Leu Met Met He Glu Glu Tyr Pro Tyr Val Val He Leu 210 215 220 GACAATTTCT TATATGATTG TCACTAATTT ATTTAAAATC AAAATTTTTA GAAAATGAAT 1079 AAATTCATTC ACAAAAATTA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1139 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAA 1172 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 320 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Met Lys He Thr Leu Ala He Ala Ser Leu Leu-Ala Leu Ser Ala Val -98 -95 -90 -85 Tyr Ala Arg Pro Ser Ser He Lys Thr Phe Glu Glu Tyr Lys Lys Ala -80 -75 -70 Phe Asn Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys -65 -60 -55 Asn Phe Leu Glu Ser Val Lys Tyr Val Gin Ser Asn Gly Gly Ala He -50 -45 -40 -35 Asn His Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu -30 -25 -20 Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr Gin Phe Asp Leu Asn -15 -10 -5 Ala Glu Thr Asn Ala Cys Ser He Asn Gly Asn Ala Pro Ala Glu He -1 1 5 10 Asp Leu Arg Gin Met Arg Thr Val Thr Pro He Arg Met Gin Gly Gly 15 20 25 30 Cys Gly Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala 35 40 45 Tyr Leu Ala His Arg Asn Gin Ser Leu Asp Leu Ala Glu Gin Glu Leu 50 55 60 Val Asp Cys Ala Ser Gin His Gly Cys His Gly Asp Thr He Pro Arg 65 70 75 Gly He Glu Tyr He Gin His Asn Gly Val Val Gin Glu Ser Tyr Tyr 80 85 90 Arg Tyr Val Ala Arg Glu Gin Ser Cys Arg Arg Pro Asn Ala Gin Arg 95 100 105 110 Phe Gly He Ser Asn Tyr Cys Gin He Tyr Pro Pro Asn Ala Asn Lys 115 120 125 He Arg Glu Ala Leu Ala Gin Thr His Ser Ala He Ala Val He He 130 135 140 Gly He Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr He 145 150 155 He Gin Arg Asp Asn Gly Tyr Gin Pro Asn Tyr His Ala Val Asn He 160 165 170 Val Gly Tyr Ser Asn Ala Gin Gly Val Asp Tyr Trp He Val Arg Asn 175 180 185 190 Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala 195 200 205 Asn He Asp Leu Met Met He Glu Glu Tyr Pro Tyr Val Val He Leu 210 215 220 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 222 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 50 (D) OTHER INFORMATION: /label=Xaa is His or Tyr (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 81 (D) OTHER INFORMATION: /label=Xaa is Glu or Lys (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 124 (D) OTHER INFORMATION: /label=Xaa is Ala or Val ( ix) FEATURE : (A) NAME/KEY: misc_feature (B) LOCATION: 136 (D) OTHER INFORMATION: /label=Xaa is Ser or Thr (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 215 (D) OTHER INFORMATION: /label=Xaa is Glu or Gin (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Thr Asn Ala Cys Ser He Asn Gly Asn Ala Pro Ala Glu He Asp Leu 1 5 10 15 Arg Gin Met Arg Thr Val Thr Pro He Arg Met Gin Gly Gly Cys Gly 20 25 30 Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu 35 40 45 Ala Xaa Arg Asn Gin Ser Leu Asp Leu Ala Glu Gin Glu Leu Val Asp 50 55 60 Cys Ala Ser Gin His Gly Cys His Gly Asp Thr He Pro Arg Gly He 65 70 75 80 Xaa Tyr He Gin His Asn Gly Val Val Gin Glu Ser Tyr Tyr Arg Tyr 85 90 95 Val Ala Arg Glu Gin Ser Cys Arg Arg Pro Asn Ala Gin Arg Phe Gly 100 105 110 Ile Ser Asn Tyr Cys Gin He Tyr Pro Pro Asn Xaa Asn Lys He Arg 115 120 125 Glu Ala Leu Ala Gin Thr His Xaa Ala He Ala Val He He Gly He 130 135 140 Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr He He Gin 145 150 155 160 Arg Asp Asn Gly Tyr Gin Pro Asn Tyr His Ala Val Asn He Val Gly 165 170 175 Tyr Ser Asn Ala Gin Gly Val Asp Tyr Trp He Val Arg Asn Ser Trp 180 185 190 Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn He 195 200 205 Asp Leu Met Met He Glu Xaa Tyr Pro Tyr Val Val He Leu 210 215 220 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 129 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ( ix) FEATURE : (A) NAME/KEY: misc_feature (B) LOCATION: 47 (D) OTHER INFORMATION: /label=Xaa is Thr or Ser (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 114 (D) OTHER INFORMATION: /label=Xaa is Asp or Asn (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 127 (D) OTHER INFORMATION: /label=Xaa is He or Leu (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Asp Gin Val Asp Val Lys Asp Cys Ala Asn His Glu He Lys Lys Val 1 5 10 15 Leu Val Pro Gly Cys His Gly Ser Glu Pro Cys He He His Arg Gly 20 25 30 Lys Pro Phe Gin Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Xaa Lys 35 40 45 Thr Ala Lys He Glu He Lys Ala Ser He Asp Gly Leu Glu Val Asp 50 55 60 Val Pro Gly He Asp Pro Asn Ala Cys His Tyr Met Lys Cys Pro Leu 65 70 75 80 Val Lys Gly Gin Gin Tyr Asp He Lys Tyr Thr Trp Asn Val Pro Lys 85 90 95 Ile Ala Pro Lys Ser Glu Asn Val Val Val Thr Val Lys Val Met Gly 100 105 110 Asp Xaa Gly Val Leu Ala Cys Ala He Ala Thr His Ala Lys Xaa Arg 115 120 125 Asp (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 129 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 11 (D) OTHER INFORMATION: /label=Xaa is Asn or Ser (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 52 (D) OTHER INFORMATION: /label=Xaa is Thr or He (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 54 (D) OTHER INFORMATION: /label=Xaa is He or Thr ( ix ) FEATURE : (A) NAME/KEY: misc_feature (B) LOCATION: 76 (D) OTHER INFORMATION: /label=Xaa is Met or Val (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 88 (D) OTHER INFORMATION: /label=Xaa is Ala or He (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 111 (D) OTHER INFORMATION: /label=Xaa is Val or He (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Asp Gin Val Asp Val Lys Asp Cys Ala Asn Xaa Glu He Lys Lys Val 1 5 10 15 Met Val Asp Gly Cys His Gly Ser Asp Pro Cys He He His Arg Gly 20 25 30 Lys Pro Phe Thr Leu Glu Ala Leu Phe Asp Ala Asn Gin Asn Thr Lys 35 40 45 Thr Ala Lys Xaa Glu Xaa Lys Ala Ser Leu Asp Gly Leu Glu He Asp 50 55 60 Val Pro Gly He Asp Thr Asn Ala Cys His Phe Xaa Lys Cys Pro Leu 65 70 75 80 Val Lys Gly Gin Gin Tyr Asp Xaa Lys Tyr Thr Trp Asn Val Pro Lys 85 90 95 Ile Ala Pro Lys Ser Glu Asn Val Val Val Thr Val Lys Leu Xaa Gly 100 105 110 Asp Asn Gly Val Leu Ala Cys Ala He Ala Thr His Ala Lys He Arg 115 120 125 Asp

Claims: CLAIMS 1. A protein allergen of Der p II comprising the amino acid sequence: Asp Gin Val Asp Val Lys Asp Cys Ala Asn His Glu He Lys Lys Val Leu Val Pro Gly Cys His Gly Ser Glu Pro Cys He He His Arg Gly Lys Pro Phe Gin Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Xaai Lys Thr Ala Lys He Glu He Lys Ala Ser He Asp Gly Leu Glu Val Asp Val Pro Gly He Asp Pro Asn Ala Cys His Tyr Met Lys Cys Pro Leu Val Lys Gly Gin Gin Tyr Asp He Lys Tyr Thr Trp Asn Val Pro Lys He Ala Pro Lys Ser Glu Asn Val Val Val Thr Val Lys Val Met Gly Xaa2 Asp Gly Val Leu Ala Cys Ala He Ala Thr His Ala Lys Xaa3 Arg Asp where Xaaj is selected from the group consisting of Thr and Ser; where Xaa2 is selected from the group consisting of Asp and Asn; and where Xaa3 is selected from the group consisting of He and Leu, except for the amino acid sequence where Xaaj is Thr, Xaa2 is Asp and Xaa3 is He. A protein allergen of Dfir f. II comprising the amino acid sequence: Asp Gin Val Asp Val Lys Asp Cys Ala Asn Xaaj Glu He Lys Lys Val Met Val Asp Gly Cys His Gly Ser Asp Pro Cys He He His Arg Gly Lys Pro Phe Thr Leu Glu Ala Leu Phe Asp Ala Asn Gin Ash Thr Lys Thr Ala Lys Xaa2 Glu Xaa3 Lys Ala Ser Leu Asp Gly Leu Glu He Asp Val Pro Gly He Asp Thr Asn Ala Cys His Phe Xaa4 Lys Cys Pro Leu Val Lys Gly Gin Gin Tyr Asp Xaa5 Lys Tyr Thr Trp Asn Val Pro Lys He Ala Pro Lys Ser Glu Asn Val Val Val Thr Val Lys Leu Xaa6 Gly Asp Asn Gly Val Leu Ala Cys Ala He Ala Thr His Ala Lys He Arg Asp where Xaai is selected from the group consisting of Asn and Ser; where Xaa2 is selected from the group consisting of Thr and He; where Xaa3 is selected from the group consisting of He and Thr; where Xaa4 is selected from the group consisting of Met and Val; where Xaa5 is selected from the group consisting of Ala and He; and where Xaag is selected from the group consisting of Val and He, with the proviso that, when Xaa] s Asn, then Xaa3 is Thr; and when Xaa3 is He, then Xaaj is Ser. 3. A therapeutic composition comprising a protein allergen of claim 1 and a pharmaceutically acceptable carrier or diluent. 4. A method of treatment for sensitivity in an individual to house dust mites, comprising administering to the individual an effective therapeutic amount of a composition of claim 3. 5. A therapeutic composition comprising a protein allergen of claim 2 and a pharmaceutically acceptable carrier or diluent. 6. A method of treatment for sensitivity in an individual to house dust mites, comprising administering to the individual an effective therapeutic amount of a composition of claim 5.

Inventors: CHUA KAW-YAN, THOMAS WAYNE R, CHUA, KAW-YAN, THOMAS, WAYNE, R.
Applicants: CHUA KAW YAN, IMMULOGIC PHARMA CORP, THOMAS WAYNE R, IMMULOGIC PHARMACEUTICAL CORPORATION
Application year: 1993
Main classification: C12N15
IPC codes: A61K38, A61K39, A61P37, C07K14, C12N15, C12P21, C12R1